JPH06504067A - 主鎖修飾されたオリゴヌクレオチド類似体 - Google Patents
主鎖修飾されたオリゴヌクレオチド類似体Info
- Publication number
- JPH06504067A JPH06504067A JP5500301A JP50030193A JPH06504067A JP H06504067 A JPH06504067 A JP H06504067A JP 5500301 A JP5500301 A JP 5500301A JP 50030193 A JP50030193 A JP 50030193A JP H06504067 A JPH06504067 A JP H06504067A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- oligonucleotide
- oligonucleotides
- substituted
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091034117 Oligonucleotide Proteins 0.000 title claims abstract description 251
- 238000000034 method Methods 0.000 claims abstract description 173
- 101710163270 Nuclease Proteins 0.000 claims abstract description 24
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 17
- 125000005647 linker group Chemical group 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 10
- 230000001105 regulatory effect Effects 0.000 claims abstract description 9
- -1 keto, benzoxy Chemical group 0.000 claims description 108
- 239000002777 nucleoside Substances 0.000 claims description 104
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 94
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 65
- 229910052799 carbon Inorganic materials 0.000 claims description 38
- 229910052760 oxygen Inorganic materials 0.000 claims description 32
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 30
- 239000000126 substance Substances 0.000 claims description 28
- 125000000217 alkyl group Chemical group 0.000 claims description 27
- 230000003285 pharmacodynamic effect Effects 0.000 claims description 27
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical group O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 26
- 238000006243 chemical reaction Methods 0.000 claims description 26
- 108090000623 proteins and genes Proteins 0.000 claims description 24
- 150000002923 oximes Chemical class 0.000 claims description 23
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- 125000003835 nucleoside group Chemical group 0.000 claims description 22
- 230000000694 effects Effects 0.000 claims description 19
- 230000007022 RNA scission Effects 0.000 claims description 18
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 17
- 150000007523 nucleic acids Chemical group 0.000 claims description 17
- 229940113082 thymine Drugs 0.000 claims description 17
- 125000003282 alkyl amino group Chemical group 0.000 claims description 16
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 16
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 16
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 16
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 15
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 15
- 229910052717 sulfur Inorganic materials 0.000 claims description 15
- 230000027455 binding Effects 0.000 claims description 14
- 238000009739 binding Methods 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- 229940035893 uracil Drugs 0.000 claims description 14
- 229930024421 Adenine Chemical group 0.000 claims description 13
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical group NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 13
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 13
- 229960000643 adenine Drugs 0.000 claims description 13
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 125000003342 alkenyl group Chemical group 0.000 claims description 11
- 125000001691 aryl alkyl amino group Chemical group 0.000 claims description 11
- 125000000623 heterocyclic group Chemical group 0.000 claims description 11
- 125000003118 aryl group Chemical group 0.000 claims description 10
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 125000005122 aminoalkylamino group Chemical group 0.000 claims description 9
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 9
- 230000002194 synthesizing effect Effects 0.000 claims description 9
- 150000001721 carbon Chemical group 0.000 claims description 8
- 229940104302 cytosine Drugs 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 8
- 229910052731 fluorine Inorganic materials 0.000 claims description 8
- 150000004713 phosphodiesters Chemical class 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- UJGVUACWGCQEAO-UHFFFAOYSA-N 1-ethylaziridine Chemical compound CCN1CC1 UJGVUACWGCQEAO-UHFFFAOYSA-N 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 7
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 7
- 125000001651 cyanato group Chemical group [*]OC#N 0.000 claims description 7
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 7
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 claims description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 7
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 6
- 230000000903 blocking effect Effects 0.000 claims description 6
- 229910052794 bromium Inorganic materials 0.000 claims description 6
- 238000003776 cleavage reaction Methods 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 150000003254 radicals Chemical class 0.000 claims description 6
- 230000007017 scission Effects 0.000 claims description 6
- 150000007970 thio esters Chemical class 0.000 claims description 6
- 125000005309 thioalkoxy group Chemical group 0.000 claims description 6
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims description 5
- 150000001336 alkenes Chemical class 0.000 claims description 5
- 150000001345 alkine derivatives Chemical class 0.000 claims description 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 238000010348 incorporation Methods 0.000 claims description 5
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 4
- 239000000908 ammonium hydroxide Substances 0.000 claims description 4
- 230000008878 coupling Effects 0.000 claims description 4
- 238000010168 coupling process Methods 0.000 claims description 4
- 238000005859 coupling reaction Methods 0.000 claims description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- PKUPAJQAJXVUEK-UHFFFAOYSA-N 2-phenoxyacetyl chloride Chemical compound ClC(=O)COC1=CC=CC=C1 PKUPAJQAJXVUEK-UHFFFAOYSA-N 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- 230000001588 bifunctional effect Effects 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 230000001172 regenerating effect Effects 0.000 claims description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 10
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 7
- 150000001299 aldehydes Chemical class 0.000 claims 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 5
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 5
- 229960005305 adenosine Drugs 0.000 claims 5
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims 3
- 229910004679 ONO2 Inorganic materials 0.000 claims 3
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims 3
- CYEBJEDOHLIWNP-UHFFFAOYSA-N methanethioamide Chemical compound NC=S CYEBJEDOHLIWNP-UHFFFAOYSA-N 0.000 claims 3
- 125000001893 nitrooxy group Chemical group [O-][N+](=O)O* 0.000 claims 3
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims 1
- 102000004316 Oxidoreductases Human genes 0.000 claims 1
- 108090000854 Oxidoreductases Proteins 0.000 claims 1
- 150000003857 carboxamides Chemical class 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000004970 halomethyl group Chemical group 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 abstract description 57
- 238000003786 synthesis reaction Methods 0.000 abstract description 48
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract description 35
- 239000002773 nucleotide Substances 0.000 abstract description 16
- 230000001225 therapeutic effect Effects 0.000 abstract description 12
- 230000004700 cellular uptake Effects 0.000 abstract description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 93
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 59
- 239000000539 dimer Substances 0.000 description 54
- 210000004027 cell Anatomy 0.000 description 50
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 43
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 42
- 239000000243 solution Substances 0.000 description 42
- 235000000346 sugar Nutrition 0.000 description 40
- 239000000203 mixture Substances 0.000 description 38
- 150000001875 compounds Chemical class 0.000 description 36
- 229940104230 thymidine Drugs 0.000 description 32
- 102100022364 Polyunsaturated fatty acid 5-lipoxygenase Human genes 0.000 description 31
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 30
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 28
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 28
- 108020004414 DNA Proteins 0.000 description 27
- 239000000047 product Substances 0.000 description 25
- 238000011282 treatment Methods 0.000 description 25
- 230000004048 modification Effects 0.000 description 21
- 238000012986 modification Methods 0.000 description 21
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 17
- 125000006239 protecting group Chemical group 0.000 description 17
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 16
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 16
- 108020004999 messenger RNA Proteins 0.000 description 15
- 230000009467 reduction Effects 0.000 description 15
- 239000007787 solid Substances 0.000 description 15
- 238000009396 hybridization Methods 0.000 description 14
- 230000000295 complement effect Effects 0.000 description 13
- 108020004707 nucleic acids Proteins 0.000 description 13
- 102000039446 nucleic acids Human genes 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- 238000005481 NMR spectroscopy Methods 0.000 description 12
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 12
- 239000000074 antisense oligonucleotide Substances 0.000 description 11
- 238000012230 antisense oligonucleotides Methods 0.000 description 11
- 238000013459 approach Methods 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 241000894007 species Species 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 239000006260 foam Substances 0.000 description 10
- 238000010898 silica gel chromatography Methods 0.000 description 10
- 238000010561 standard procedure Methods 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 229910001868 water Inorganic materials 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- 150000008300 phosphoramidites Chemical class 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 229910052786 argon Inorganic materials 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- 229910052698 phosphorus Inorganic materials 0.000 description 8
- 230000014616 translation Effects 0.000 description 8
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 7
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 7
- 230000000692 anti-sense effect Effects 0.000 description 7
- 229940114079 arachidonic acid Drugs 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 235000019439 ethyl acetate Nutrition 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 6
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 235000021342 arachidonic acid Nutrition 0.000 description 6
- 239000010452 phosphate Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 101150041968 CDC13 gene Proteins 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000013626 chemical specie Substances 0.000 description 5
- 229930189851 creoside Natural products 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- IDBOAVAEGRJRIZ-UHFFFAOYSA-N methylidenehydrazine Chemical compound NN=C IDBOAVAEGRJRIZ-UHFFFAOYSA-N 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- HODJXCXFLDRJJH-UHFFFAOYSA-N 1-ethenyl-2-methylhydrazine Chemical compound C=CNNC HODJXCXFLDRJJH-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 230000006820 DNA synthesis Effects 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 4
- 238000000376 autoradiography Methods 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 235000008504 concentrate Nutrition 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 150000002617 leukotrienes Chemical class 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 238000002515 oligonucleotide synthesis Methods 0.000 description 4
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 4
- 238000004007 reversed phase HPLC Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 229940045145 uridine Drugs 0.000 description 4
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 3
- 125000002596 5'-thymidylyl group Chemical group [H]C1=C(C([H])([H])[H])C(=O)N([H])C(=O)N1[C@@]1([H])C([H])([H])[C@@](O[H])([H])[C@](C(OP(=O)(O[H])[*])([H])[H])([H])O1 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 238000005654 Michaelis-Arbuzov synthesis reaction Methods 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- HIYAVKIYRIFSCZ-UHFFFAOYSA-N calcium ionophore A23187 Natural products N=1C2=C(C(O)=O)C(NC)=CC=C2OC=1CC(C(CC1)C)OC1(C(CC1C)C)OC1C(C)C(=O)C1=CC=CN1 HIYAVKIYRIFSCZ-UHFFFAOYSA-N 0.000 description 3
- 125000002837 carbocyclic group Chemical group 0.000 description 3
- 108091092328 cellular RNA Proteins 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 101150014604 cpg-3 gene Proteins 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 150000007857 hydrazones Chemical class 0.000 description 3
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 3
- 239000013067 intermediate product Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 125000004437 phosphorous atom Chemical group 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000001243 protein synthesis Methods 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- FAGLEPBREOXSAC-UHFFFAOYSA-N tert-butyl isocyanide Chemical compound CC(C)(C)[N+]#[C-] FAGLEPBREOXSAC-UHFFFAOYSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- YAHHPOUXPBUKTL-DXKBKMAZSA-N thymidine dimer Chemical compound CC12C(C3N([C@H]4C[C@H](O)[C@@H](CO)O4)C(=O)NC(=O)C13C)N([C@H]1C[C@H](O)[C@@H](CO)O1)C(=O)NC2=O YAHHPOUXPBUKTL-DXKBKMAZSA-N 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- ZQXCQTAELHSNAT-UHFFFAOYSA-N 1-chloro-3-nitro-5-(trifluoromethyl)benzene Chemical compound [O-][N+](=O)C1=CC(Cl)=CC(C(F)(F)F)=C1 ZQXCQTAELHSNAT-UHFFFAOYSA-N 0.000 description 2
- CFMZSMGAMPBRBE-UHFFFAOYSA-N 2-hydroxyisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(O)C(=O)C2=C1 CFMZSMGAMPBRBE-UHFFFAOYSA-N 0.000 description 2
- 125000002103 4,4'-dimethoxytriphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)(C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H])C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 2
- HIYAVKIYRIFSCZ-CYEMHPAKSA-N 5-(methylamino)-2-[[(2S,3R,5R,6S,8R,9R)-3,5,9-trimethyl-2-[(2S)-1-oxo-1-(1H-pyrrol-2-yl)propan-2-yl]-1,7-dioxaspiro[5.5]undecan-8-yl]methyl]-1,3-benzoxazole-4-carboxylic acid Chemical compound O=C([C@@H](C)[C@H]1O[C@@]2([C@@H](C[C@H]1C)C)O[C@@H]([C@@H](CC2)C)CC=1OC2=CC=C(C(=C2N=1)C(O)=O)NC)C1=CC=CN1 HIYAVKIYRIFSCZ-CYEMHPAKSA-N 0.000 description 2
- ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 description 2
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 229910014033 C-OH Inorganic materials 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 229910014570 C—OH Inorganic materials 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- GMPKIPWJBDOURN-UHFFFAOYSA-N Methoxyamine Chemical class CON GMPKIPWJBDOURN-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000005289 controlled pore glass Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 239000005549 deoxyribonucleoside Substances 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000006345 epimerization reaction Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 238000007327 hydrogenolysis reaction Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 125000005699 methyleneoxy group Chemical group [H]C([H])([*:1])O[*:2] 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 238000005731 phosphitylation reaction Methods 0.000 description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 2
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 2
- 125000005543 phthalimide group Chemical group 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- SCHZCUMIENIQMY-UHFFFAOYSA-N tris(trimethylsilyl)silicon Chemical compound C[Si](C)(C)[Si]([Si](C)(C)C)[Si](C)(C)C SCHZCUMIENIQMY-UHFFFAOYSA-N 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 2
- ZRVAZLVAQKILLT-AMCGLFBUSA-N (2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-2-(hydroxymethyl)oxolane-3-carbaldehyde Chemical class OC[C@H]1O[C@H]([C@H](O)[C@@]1(O)C=O)n1ccc(=O)[nH]c1=O ZRVAZLVAQKILLT-AMCGLFBUSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- GKEHVJFBPNPCKI-XLPZGREQSA-N 1-[(2r,4s,5r)-5-(azidomethyl)-4-hydroxyoxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CN=[N+]=[N-])[C@@H](O)C1 GKEHVJFBPNPCKI-XLPZGREQSA-N 0.000 description 1
- QDHQPUTUFOHTGE-UHFFFAOYSA-N 1-[1-hydroxy-1-(methylamino)ethyl]sulfanyloxysulfanyl-1-(methylamino)ethanol Chemical compound CNC(SOSC(NC)(C)O)(O)C QDHQPUTUFOHTGE-UHFFFAOYSA-N 0.000 description 1
- UUFQTNFCRMXOAE-UHFFFAOYSA-N 1-methylmethylene Chemical compound C[CH] UUFQTNFCRMXOAE-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 description 1
- BPMXOBNFOWJWKL-UHFFFAOYSA-N 2,3,4-triphenylphosphinine Chemical compound C1=CC=CC=C1C1=CC=PC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 BPMXOBNFOWJWKL-UHFFFAOYSA-N 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- ZNJRONVKWRHYBF-UHFFFAOYSA-N 2-[2-[2-(1-azatricyclo[7.3.1.05,13]trideca-5,7,9(13)-trien-7-yl)ethenyl]-6-methylpyran-4-ylidene]propanedinitrile Chemical compound O1C(C)=CC(=C(C#N)C#N)C=C1C=CC1=CC(CCCN2CCC3)=C2C3=C1 ZNJRONVKWRHYBF-UHFFFAOYSA-N 0.000 description 1
- BIVIXXXEPPIGSS-UHFFFAOYSA-N 2-[amino(propan-2-yloxy)phosphanyl]oxypropane Chemical class CC(C)OP(N)OC(C)C BIVIXXXEPPIGSS-UHFFFAOYSA-N 0.000 description 1
- VRVRGVPWCUEOGV-UHFFFAOYSA-N 2-aminothiophenol Chemical compound NC1=CC=CC=C1S VRVRGVPWCUEOGV-UHFFFAOYSA-N 0.000 description 1
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 1
- AGIJRRREJXSQJR-UHFFFAOYSA-N 2h-thiazine Chemical compound N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 description 1
- VHNPUSDRWNRJOU-UHFFFAOYSA-N 3-(hydroxymethyl)-3h-2-benzofuran-1-one Chemical compound C1=CC=C2C(CO)OC(=O)C2=C1 VHNPUSDRWNRJOU-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical class N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 240000008100 Brassica rapa Species 0.000 description 1
- ZDVSEBLMCKBONL-ZENOOKHLSA-N C1(=CC=CC=C1)[SiH2][C@@]1(C[C@H](O)[C@@H](CO)O1)N1C(=O)NC(=O)C(C)=C1 Chemical compound C1(=CC=CC=C1)[SiH2][C@@]1(C[C@H](O)[C@@H](CO)O1)N1C(=O)NC(=O)C(C)=C1 ZDVSEBLMCKBONL-ZENOOKHLSA-N 0.000 description 1
- 101100167062 Caenorhabditis elegans chch-3 gene Proteins 0.000 description 1
- 101100021265 Caenorhabditis elegans lin-5 gene Proteins 0.000 description 1
- 101100294106 Caenorhabditis elegans nhr-3 gene Proteins 0.000 description 1
- HIYAVKIYRIFSCZ-CVXKHCKVSA-N Calcimycin Chemical compound CC([C@H]1OC2([C@@H](C[C@H]1C)C)O[C@H]([C@H](CC2)C)CC=1OC2=CC=C(C(=C2N=1)C(O)=O)NC)C(=O)C1=CC=CN1 HIYAVKIYRIFSCZ-CVXKHCKVSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000573199 Homo sapiens Protein PML Proteins 0.000 description 1
- 206010050789 Hypochromasia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GWNVDXQDILPJIG-SHSCPDMUSA-N Leukotriene C4 Natural products CCCCCC=C/CC=C/C=C/C=C/C(SCC(NC(=O)CCC(N)C(=O)O)C(=O)NCC(=O)O)C(O)CCCC(=O)O GWNVDXQDILPJIG-SHSCPDMUSA-N 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699673 Mesocricetus auratus Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 101100170604 Mus musculus Dmap1 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- 241001274216 Naso Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 239000004727 Noryl Substances 0.000 description 1
- 229920001207 Noryl Polymers 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- SYXQUFVBOQEGMQ-UHFFFAOYSA-N P(=O)(OC1=CC=CC=C1)(O)O.CC1=C(C=CC=C1)P(C1=CC=CC=C1)C1=CC=CC=C1.CC1=C(C=CC=C1)P(C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound P(=O)(OC1=CC=CC=C1)(O)O.CC1=C(C=CC=C1)P(C1=CC=CC=C1)C1=CC=CC=C1.CC1=C(C=CC=C1)P(C1=CC=CC=C1)C1=CC=CC=C1 SYXQUFVBOQEGMQ-UHFFFAOYSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710149951 Protein Tat Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 238000003457 Shi epoxidation reaction Methods 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical class [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- IRFKBRPHBYCMQU-IVZWLZJFSA-N [(2r,3s,5r)-2-(hydroxymethyl)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-3-yl] acetate Chemical compound O1[C@H](CO)[C@@H](OC(=O)C)C[C@@H]1N1C(=O)NC(=O)C(C)=C1 IRFKBRPHBYCMQU-IVZWLZJFSA-N 0.000 description 1
- FTNBHMNTVIOKMK-UHFFFAOYSA-N [Th].B[H] Chemical compound [Th].B[H] FTNBHMNTVIOKMK-UHFFFAOYSA-N 0.000 description 1
- SPOIGTPLXYZKBM-UHFFFAOYSA-N [Zn].O=P(OC1=CC=CC=C1)OC1=CC=CC=C1 Chemical class [Zn].O=P(OC1=CC=CC=C1)OC1=CC=CC=C1 SPOIGTPLXYZKBM-UHFFFAOYSA-N 0.000 description 1
- DKFCLGCDEMSYAW-UHFFFAOYSA-N [iodo(diphenyl)methyl]benzene Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(I)C1=CC=CC=C1 DKFCLGCDEMSYAW-UHFFFAOYSA-N 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- WFKAJVHLWXSISD-UHFFFAOYSA-N anhydrous dimethyl-acetamide Natural products CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 238000000211 autoradiogram Methods 0.000 description 1
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- KXAJABNDLZOYRG-UHFFFAOYSA-N benzyl n-oxocarbamate Chemical compound O=NC(=O)OCC1=CC=CC=C1 KXAJABNDLZOYRG-UHFFFAOYSA-N 0.000 description 1
- 238000005574 benzylation reaction Methods 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical class CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000003710 calcium ionophore Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
- 150000001717 carbocyclic compounds Chemical class 0.000 description 1
- 229910002090 carbon oxide Inorganic materials 0.000 description 1
- XEVRDFDBXJMZFG-UHFFFAOYSA-N carbonyl dihydrazine Chemical compound NNC(=O)NN XEVRDFDBXJMZFG-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000006315 carbonylation Effects 0.000 description 1
- 238000005810 carbonylation reaction Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- WBLIXGSTEMXDSM-UHFFFAOYSA-N chloromethane Chemical compound Cl[CH2] WBLIXGSTEMXDSM-UHFFFAOYSA-N 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- JEVCWSUVFOYBFI-UHFFFAOYSA-N cyanyl Chemical compound N#[C] JEVCWSUVFOYBFI-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006392 deoxygenation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- YLFBFPXKTIQSSY-UHFFFAOYSA-N dimethoxy(oxo)phosphanium Chemical compound CO[P+](=O)OC YLFBFPXKTIQSSY-UHFFFAOYSA-N 0.000 description 1
- NALBLJLOBICXRH-UHFFFAOYSA-N dinitrogen monohydride Chemical compound N=[N] NALBLJLOBICXRH-UHFFFAOYSA-N 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- PONXTPCRRASWKW-KBPBESRZSA-N diphenylethylenediamine Chemical compound C1([C@H](N)[C@@H](N)C=2C=CC=CC=2)=CC=CC=C1 PONXTPCRRASWKW-KBPBESRZSA-N 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- CJAONIOAQZUHPN-KKLWWLSJSA-N ethyl 12-[[2-[(2r,3r)-3-[2-[(12-ethoxy-12-oxododecyl)-methylamino]-2-oxoethoxy]butan-2-yl]oxyacetyl]-methylamino]dodecanoate Chemical compound CCOC(=O)CCCCCCCCCCCN(C)C(=O)CO[C@H](C)[C@@H](C)OCC(=O)N(C)CCCCCCCCCCCC(=O)OCC CJAONIOAQZUHPN-KKLWWLSJSA-N 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- QRMKTNANRJCRCY-UHFFFAOYSA-N ethylammonium acetate Chemical compound CC[NH3+].CC([O-])=O QRMKTNANRJCRCY-UHFFFAOYSA-N 0.000 description 1
- GATNOFPXSDHULC-UHFFFAOYSA-N ethylphosphonic acid Chemical compound CCP(O)(O)=O GATNOFPXSDHULC-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 102000054896 human PML Human genes 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 1
- 125000005597 hydrazone group Chemical group 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- XNXVOSBNFZWHBV-UHFFFAOYSA-N hydron;o-methylhydroxylamine;chloride Chemical compound Cl.CON XNXVOSBNFZWHBV-UHFFFAOYSA-N 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 101150001870 incC gene Proteins 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 150000002497 iodine compounds Chemical class 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000002555 ionophore Substances 0.000 description 1
- 230000000236 ionophoric effect Effects 0.000 description 1
- LRDFRRGEGBBSRN-UHFFFAOYSA-N isobutyronitrile Chemical compound CC(C)C#N LRDFRRGEGBBSRN-UHFFFAOYSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- XMYQHJDBLRZMLW-UHFFFAOYSA-N methanolamine Chemical compound NCO XMYQHJDBLRZMLW-UHFFFAOYSA-N 0.000 description 1
- AZFQCTBZOPUVOW-UHFFFAOYSA-N methyl(triphenyl)phosphanium Chemical compound C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 AZFQCTBZOPUVOW-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- PADPKJACPLYMPK-UHFFFAOYSA-N n',n'-diphenylethane-1,2-diamine Chemical class C=1C=CC=CC=1N(CCN)C1=CC=CC=C1 PADPKJACPLYMPK-UHFFFAOYSA-N 0.000 description 1
- VUAAUVMKUNKSNE-UHFFFAOYSA-N n,n'-diphenylethene-1,2-diamine Chemical group C=1C=CC=CC=1NC=CNC1=CC=CC=C1 VUAAUVMKUNKSNE-UHFFFAOYSA-N 0.000 description 1
- OWIUPIRUAQMTTK-UHFFFAOYSA-M n-aminocarbamate Chemical compound NNC([O-])=O OWIUPIRUAQMTTK-UHFFFAOYSA-M 0.000 description 1
- SXNHGPBUYWPVPF-UHFFFAOYSA-N n-hydrazinylhydroxylamine Chemical compound NNNO SXNHGPBUYWPVPF-UHFFFAOYSA-N 0.000 description 1
- SQDFHQJTAWCFIB-UHFFFAOYSA-N n-methylidenehydroxylamine Chemical class ON=C SQDFHQJTAWCFIB-UHFFFAOYSA-N 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- CDXVUROVRIFQMV-UHFFFAOYSA-N oxo(diphenoxy)phosphanium Chemical compound C=1C=CC=CC=1O[P+](=O)OC1=CC=CC=C1 CDXVUROVRIFQMV-UHFFFAOYSA-N 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000009057 passive transport Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- RPGWZZNNEUHDAQ-UHFFFAOYSA-N phenylphosphine Chemical compound PC1=CC=CC=C1 RPGWZZNNEUHDAQ-UHFFFAOYSA-N 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 150000003017 phosphorus Chemical class 0.000 description 1
- 229910001392 phosphorus oxide Inorganic materials 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical class [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 239000002212 purine nucleoside Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 239000002718 pyrimidine nucleoside Substances 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- GGWBHVILAJZWKJ-KJEVSKRMSA-N ranitidine hydrochloride Chemical compound [H+].[Cl-].[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 GGWBHVILAJZWKJ-KJEVSKRMSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001846 repelling effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- LIVNPJMFVYWSIS-UHFFFAOYSA-N silicon monoxide Chemical class [Si-]#[O+] LIVNPJMFVYWSIS-UHFFFAOYSA-N 0.000 description 1
- 229910052814 silicon oxide Chemical class 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- 238000006884 silylation reaction Methods 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 239000011593 sulfur Chemical class 0.000 description 1
- XTQHKBHJIVJGKJ-UHFFFAOYSA-N sulfur monoxide Chemical class S=O XTQHKBHJIVJGKJ-UHFFFAOYSA-N 0.000 description 1
- 229910052815 sulfur oxide Inorganic materials 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 150000005671 trienes Chemical class 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000005866 tritylation reaction Methods 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- DNYWZCXLKNTFFI-UHFFFAOYSA-N uranium Chemical compound [U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U] DNYWZCXLKNTFFI-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Electric Double-Layer Capacitors Or The Like (AREA)
- Organic Insulating Materials (AREA)
- Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
Abstract
Description
Claims (96)
- 1.オリゴヌクレオチド類似体であって、該類似体の少なくとも−部のサブユニ ットが次の構造: ▲数式、化学式、表等があります▼ [式中、 Bxは可変の塩基部分であり; QはO,CH2,CHF,またはCF2であり;XはH,OH,C1〜C10低 級アルキル,置換低級アルキル,アルカリール,アラルキル,F,Cl,Br, CN,CF3,OCF3,OCN,O−アルキル,S−アルキル,N−アルキル ,O−アルケニル,S−アルケニル,N−アルケニル,SOCH3,SO2CH 3,ONO2,NO2,N3,NH2,ヘテロシクロアルキル,ヘテロシクロア ルカリール,アミノアルキルアミノ,ポリアルキルアミノ,置換シリル,RNA 開裂基、オリゴヌクレオチドの薬物動態学的特性を改良するための基、またはオ リゴヌクレオチドの薬力学的特性を改良するための基であり;L1およびL4は 互いに独立的に、CH2,C=O,C=S,C−NH2,C−NHR3,C−O H,C−SH,C−O−R1,またはC−S−R1であり;L2およびL3は互 いに独立的に、CR1R2,C=CR1R2,C=NR3,P(O)R4,P( S)R4,C=O,C=S,O,S,SO,SO2,NR3,もしくはSiR5 R6であるか、あるいは一緒になってアルケン、アルキン、芳香環、炭素環、も しくは複素環の一部を形成するか、あるいは、L1,L2,L3,およびL1は 、一緒になって−CH=N−NH−CH2−部分,または−CH2−O−N=C H−部分を構成し;R1よびR2は互いに独立的に、H,OH,SH,NH2, C1〜C10アルキル,置換アルキル,アルケニル,アルカリール,アラルキル ,アルコキシ,チオアルコキシ,アルキルアミノ,アラルキルアミノ,置換アル キルアミノ,ヘテロシクロアルキル,ヘテロシクロアルキルアミノ,アミノアル キルアミノ,ポリアルキルアミノ,ハロ,ホルミル,ケト,ベンゾキシ,カルボ キサミド,チオカルボキサミド,エステル,チオエステル,カルボキサミジン, カルバミル,ウレイド,グアニジノ,RNA開裂基、オリゴヌクレオチドの薬物 動態学的特性を改良するための基、またはオリゴヌクレオチドの薬力学的特性を 改良するための基であり; R3は、H,OH,NH2,低級アルキル,置換低級アルキル,アルコキシ,低 級アルケニル,アラルキル,アルキルアミノ,アラルキルアミノ,置換アルキル アミノ,ヘテロシクロアルキル,ヘテロシクロアルキルアミノ,アミノアルキル アミノ,ポリアルキルアミノ,RNA開裂基、オリゴヌクレオチドの薬物動態学 的特性を改良するための基、またはオリゴヌクレオチドの薬力学的特性を改良す るための基であり; R4は、OH,SH,NH2,O−アルキル,S−アルキル,NH−アルキル, O−アルキルヘテロシクロ,S−アルキルヘテロシクロ,N−アルキルヘテロシ クロ,または窒素含有複素環であり; R5およびR6は、それぞれ独立的にC1〜C5アルキルまたはC1〜C6アル コキシである; ただし、L1がC=OまたはC=Sであるときは、L2はNR3ではなく;L4 がC=OまたはC=Sであるときは、L3はNR3ではなく:L2またはL3の 一方がC=OまたはC=Sであるときは、L2またはL3の他方はNR3ではな く;L2がP(O)R4であり,R4がOHであり,XがOHであり,かつ、B xがウラシルまたはアデニンであるときは,L3はOではなく;またL1,L2 .およびL1がCH2であり,XがHまたはOHであり,かつ、QがOであると きは,L3はS,SO,またはSO2ではない] を有する、オリゴヌクレオチド類似体。
- 2.QがOである、請求項1記載のオリゴヌクレオチド類似体。
- 3.L1およびL4がそれぞれCR1R2である、請求項1記載のオリゴヌクレ オチド類似体。
- 4.R1およびR2がそれぞれHである、請求項3記載のオリゴヌクレオチド類 似体。
- 5.QがOである、請求項4記載のオリゴヌクレオチド類似体。
- 6.L2およびL3か互いに独立的に、CR1R2,O,P(O)R4,P(S )R4,またはNR3である、請求項1記載のオリゴヌクレオチド類似体。
- 7.L2とL3の一方がCR1R2であり、L2とL3の他方がP(O)R4ま たはP(S)R4である、請求項6記載のオリゴヌクレオチド類似体。
- 8.L2がOであり、L3がP(O)R4またはP(S)R4である、請求項6 記載のオリゴヌクレオチド類似体。
- 9.L2およびL3がそれぞれNR3である、請求項1記載のオリゴヌクレオチ ド類似体。
- 10.R3がHである、請求項9記載のオリゴヌクレオチド類似体。
- 11.L1およびL4がそれぞれCH2であり、L2およびL3がそれぞれNR 3である、請求項1記載のオリゴヌクレオチド類似体。
- 12.L2とL3が一緒になって、シクロプロピル、シクロブチル、エチレンオ キシ、エチルアジリジン、または置換エチルアジリジン環の一部を形成している 、請求項1記載のオリゴヌクレオチド類似体。
- 13.L2とL3が一緒になって、C3〜C6炭素環、または4,5,もしくは 6員構成の窒素複素環を形成している、請求項1記載のオリゴヌクレオチド類似 体。
- 14.XがHである、請求項1記載のオリゴヌクレオチド類似体。
- 15.XがOHである、請求項1記載のオリゴヌクレオチド類似体。
- 16.XがH、OH、F、O−アルキル、またはO−アルケニルであり、かつ、 QがOである、請求項1記載のオリゴヌクレオチド類似体。
- 17.Bxが、アデニン、グアニン、ウラシル、チミン、シトシン、2−アミノ アデノシン、または5−メチルシトシンである、請求項1記載のオリゴヌクレオ チド類似体。
- 18.QがOである、請求項17記載のオリゴヌクレオチド類似体。
- 19.L1およびL4がそれぞれCH2である、請求項21記載のオリゴヌクレ オチド類似体。
- 20.L2およびL3がそれぞれNHである、請求項19記載のオリゴヌクレオ チド類似体。
- 21.L2とL3の一方がOであり、L2とL3の他方がNHである、請求項1 9記載のオリゴヌクレオチド類似体。
- 22.L2がNHであり、L3がOである、請求項19記載のオリゴヌクレオチ ド類似体。
- 23.L2がOであり、L3がNHである、請求項21記載のオリゴヌクレオチ ド類似体。
- 24.前記の横這を有するサブユニットを約5〜50個含む、請求項1記載のオ リゴヌクレオチド類似体。
- 25.実質的にすべてのサブユニットが前記の構造を有する、請求項1記載のオ リゴヌクレオチド類似体。
- 26.実質的に交互のサブユニットが前記の構造を有する、請求項1記載のオリ ゴヌクレオチド類似体。
- 27.医薬用として許容しうるキャリヤー中に含まれる、請求項1記載のオリゴ ヌクレオチド類似体。
- 28.対応する天然のオリゴヌクレオチドに比べて、改良された耐ヌクレアーゼ 性を示す、請求項1記載のオリゴヌクレオチド類似体。
- 29.生物中における蛋白質の生成と活性を調節する方法であって、該蛋白質を コードする核酸配列の少なくとも一部と特異的にハイブリッド形成することが可 能なオリゴヌクレオチド類似体と該生物とを接触させることを含み、ここで類似 体のサブユニットの少なくともいくつかが次の構造:▲数式、化学式、表等があ ります▼ [式中、 Bxは可変の塩基部分であり; QはO,CH2,CHF,またはCF2であり;XはH,OH,C1〜C10低 級アルキル,置換低級アルキル,アルカリール,アラルキル,F,Cl,Br, CN,CF3,OCF3,OCN,O−アルキル,S−アルキル,N−アルキル ,O−アルケニル,S−アルケニル,N−アルケニル,SOCH3,SO2CH 3,ONO2,NO2,N3,NH2,ヘテロシクロアルキル,ヘテロシクロア ルカリール,アミノアルキルアミノ,ポリアルキルアミノ,置換シリル,RNA 開裂基、オリゴヌクレオチドの薬物動態学的特性を改良するための基、またはオ リゴヌクレオチドの薬力学的特性を改良するための基であり;L1およびL4は 互いに独立的に、CH2,C=O,C=S,C−NH2,C−NHR3,C−O H,C−SH,C−O−R1,またはC−S−R1であり;L2およびL3は互 いに独立的に、CR1R2,C=CR1R2,C=NR3,P(O)R4,P( S)R4,C=O,C=S,O,S,SO,SO2,NR3,もしくはSiR5 R6であるか、あるいは一緒になってアルケン、アルキン、芳香環、炭素環、も しくは複素環の一部を形成するか、あるいは、L1,L2,L3,およびL4は 、一緒になって−CH=N−NH−CH2−部分,または−CH2−O−N=C H−部分を構成し;R1およびR2は互いに独立的に、H,OH,SH,NH2 ,C1〜C10アルキル,置換アルキル,アルケニル,アルカリール,アラルキ ル,アルコキシ,チオアルコキシ,アルキルアミノ,アラルキルアミノ,置換ア ルキルアミノ,ヘテロシクロアルキル,ヘテロシクロアルキルアミノ,アミノア ルキルアミノ,ポリアルキルアミノ,ハロ,ホルミル,ケト,ベンゾキシ,カル ボキサミド,チオカルボキサミド,エステル,チオエステル,カルボキサミジン ,カルバミル,ウレイド,グアニジノ,RNA開裂基、オリゴヌクレオチドの薬 物動態学的特性を改良すうための基、またはオリゴヌクレオチドの薬力学的特性 を改良するための基であり; R3は、H,OH,NH2,低級アルキル,置換低級アルキル,アルコキシ,低 級アルケニル,アラルキル,アルキルアミノ,アラルキルアミノ,置換アルキル アミノ,ヘテロシクロアルキル,ヘテロシクロアルキルアミノ,アミノアルキル アミノ,ポリアルキルアミノ,RNA開裂基、オリゴヌクレオチドの薬物動態学 的特性を改良するための基、またはオリゴヌクレオチドの薬力学的特性を改良す るための基であり; R4は、OH,SH,NH2,O−アルキル,S−アルキル,NH−アルキル, O−アルキル複素瑛,S−アルキル複素環,N−アルキル複素環,または窒素含 有複素環であり; R5およびR6は、それぞれ独立的にC1〜C6アルキルまたはC1〜C6アル コキシである; ただし、L1がC=OまたはC=Sであるときは、L2はNR3ではなく;L4 がC=OまたはC=Sであるときは、L3はNR3ではなく;L2またはL3の 一方がC=OまたはC=Sであるときは、L2またはL3の他方はNR3ではな く;L2がP(O)R4であり,R4がOHであり,XがOHであり,かつ、B xがウラシルまたはアデニンであるときは,L3はOではなく;またL1,L2 ,およびL4がCH2であり,XがHまたはOHであり,かつ、QがOであると きは,L3はS,SO,またはSO2ではない] を有することを特徴とする方法。
- 30.QがOである、請求項29記載の方法。
- 31.L1およびL4がそれぞれCR1R2である、請求項29記載の方法。
- 32.R1およびR2がそれぞれHである、請求項31記載の方法。
- 33.QがOである、請求項32記載の方法。
- 34.L2およびL3が互いに独立的に、CR1R2,O,P(O)R4,P( S)R4,またはNR3である、請求項29記載の方法。
- 35.L2とL3の一方がCR1R2であり、L2とL3の他方がP(O)R4 またはP(S)R4である、請求項34記載の方法。
- 36.L2がOであり、L3がP(O)R4またはP(S)R4である、請求項 34記載の方法。
- 37.L2およびL3がそれぞれNR3である、請求項29記載の方法。
- 38.R3がHである、請求項37記載のオリゴヌクレオチド類似体。
- 39.L1およびL4がそれぞれCH2であり、L2およびL3がそれぞれNR 3である、請求項29記載の方法。
- 40.L2とL3が一緒になって、シクロプロピル、シクロブチル、エチレンオ キシ、エチルアジリジン、または置換エチルアジリジン環の一部を形成している 、請求項29記載の方法。
- 41.L2とL3が一緒になって、C3〜C6炭素環、または4,5,もしくは 6員構成の窒素複素環を形成している、請求項29記載の方法。
- 42.XがHである、請求項29記載の方法。
- 43.XがOHである、請求項29記載の方法。
- 44.XがH、OH、F、O−アルキル、またはO−アルケニルであり、かつ、 QがOである、請求項29記載の方法。
- 45.Bxが、アデニン、グアニン、ウラシル、チミン、シトシン、2−アミノ アデノシン、または5−メチルシトシンである、請求項29記載の方法。
- 46.QがOである、請求項45記載の方法。
- 47.L1およびL4がそれぞれCH2である、請求項46記載の方法。
- 48.L2およびL3がそれぞれNHである、請求項47記載の方法。
- 49.L2とL3の一方がOであり、L2とL3の他方がNHである、請求項4 7記載の方法。
- 50.L2がNHであり、L3がOである、請求項47記載の方法。
- 51.L2がOであり、L3がNHである、請求項47記載の方法。
- 52.オリゴヌクレオチド類似体が前記の構造を有するサブユニットを約5〜5 0個含む、請求項29記載の方法。
- 53.オリゴヌクレオチド類似体の実質的にすべてのサブユニットが前記の構造 を有する、請求項29記載の方法。
- 54.オリゴヌクレオチド類似体の実質的に交互のサブユニットが前記の構造を 有する、請求項29記載の方法。
- 55.オリゴヌクレオチド類似体が医薬用として許容しうるキャリヤー中に含ま れる、請求項29記載の方法。
- 56.オリゴヌクレオチド類似体が対応する天然のオリゴヌクレオチドに比べて 、改良された耐ヌクレアーゼ性を示す、請求項29記載の方法。
- 57.蛋白質の望ましくない生成を特徴とする疾患を有する生物を処置する方法 であって、該蛋白質をコードする核酸配列の少なくとも一部とハイブリッド形成 することが可能なオリゴヌクレオチド類似体と該生物とを、単独もしくは医薬用 として許容しうるキャリやー中に製剤した形で接触させることを含み、ここで前 記類似体のサブユニットの少なくともいくつかが次の構造:▲数式、化学式、表 等があります▼ [式中、 Bxは可変の塩基部分であり; QはO,CH2,CHF,またはCF2であり;XはH,OH,C1〜C10低 級アルキル,置換低級アルキル,アルカリール,アラルキル,F,Cl,Br, CN,CF3,OCF3,OCN,O−アルキル,S−アルキル,N−アルキル ,O−アルケニル,S−アルケニル,N−アルケニル,SOCH3,SO2CH 3,ON02,NO2,N3,NH2,ヘテロシクロアルキル,ヘテロシクロア ルカリール,アミノアルキルアミノ,ポリアルキルアミノ,置換シリル,RNA 開裂基、オリゴヌクレオチドの薬物動態学的特性を改良するための基、またはオ リゴヌクレオチドの薬力学的特性を改良するための基であり;L1およびL4は 互いに独立的に、CH2,C=O,C=S,C−NH2,C−NHR3,C−O H,C−SH,C−O−R1,またはC−S−R1であり;L2およびL3は互 いに独立的に、CR1R2,C=CR1R2,C=NR3,P(O)R4,P( S)R4,C=O,C=S,O,S,SO,SO2,NR3,もしくはSiR5 R6であるか、あるいは一緒になってアルケン、アルキン、芳香環、炭素環、も しくは複素環の一部を形成するか、あるいは、L1,L2,L3,およびL4は 、一緒になって−CH=N−NH−CH2−部分,または−CH2−O−N=C H−部分を構成し:R1およびR2は互いに独立的に、H,OH,SH,NH2 ,C1〜C10アルキル,置換アルキル,アルケニル,アルカリール,アラルキ ル,アルコキシ,チオアルコキシ,アルキルアミノ,アラルキルアミノ,置換ア ルキルアミノ,ヘテロシクロアルキル,ヘテロシクロアルキルアミノ,アミノア ルキルアミノ,ポリアルキルアミノ,ハロ,ホルミル,ケト,ベンゾキシ,カル ボキサミド,チオカルボキサミド,エステル,チオエステル,カルボキサミジン ,カルバミル,ウレイド,グアニジノ,RNA開裂基、オリゴヌクレオチドの薬 物動態学的特性を改良するための基、またはオリゴヌクレオチドの薬力学的特性 を改良するための基であり; R3は、H,OH,NH2,低級アルキル,置換低級アルキル,アルコキシ,低 級アルケニル,アラルキル,アルキルアミノ,アラルキルアミノ,置換アルキル アミノ,ヘテロシクロアルキル,ヘテロシクロアルキルアミノ,アミノアルキル アミノ,ポリアルキルアミノ,RNA開裂基、オリゴヌクレオチドの薬物動態学 的特性を改良するための基、またはオリゴヌクレオチドの薬力学的特性を改良す るための基であり: R4は、OH,SH,NH2,O−アルキル,S−アルキル,NH−アルキル, O−アルキル複素環,S−アルキル複素環,N−アルキル複素環,または窒素含 有複素環であり; R5およびR6は、それぞれ独立的にC1〜C6アルキルまたはC1〜C6アル コキシである; ただし、L1がC=OまたはC=Sであるときは、L2はNR3ではなく;L4 がC=OまたはC=Sであるときは、L3はNR3ではなく;L2またはL3の 一方がC=OまたはC=Sであるときは、L2またはL3の他方はNR3ではな く;L2がP(O)R4であり,R4がOHであり,XがOHであり,かつ、B 2がウラシルまたはアデニンであるときは,L3はOではなく;またL1,L2 ,およびL4がCH2であり,XがHまたはOHであり,かつ、QがOであると きは,L3はS,SO,またはSO2ではない] を有することを特徴とする方法。
- 58.QがOである、請求項57記載の方法。
- 59.L1およびL4がそれぞれCR1R2である、請求項57記載の方法。
- 60.R1およびR2がそれぞれHである、請求項59記載の方法。
- 61.QがOである、請求項60記載の方法。
- 62.L2およびL3が互いに独立的に、CR1R2,O,P(O)R4,P( S)R4,またはNR3である、請求項57記載の方法。
- 63.L2とL3の一方がCR1R2であり、L2とL3の他方がP(O)R4 またはP(S)R4である、請求項62記載の方法。
- 64.L2がOであり、L3がP(O)R4またはP(S)R4である、請求項 62記載の方法。
- 65.L2およびL3がそれぞれNR3である、請求項57記載の方法。
- 66.R3がHである、請求項65記載の方法。
- 67.L1およびL4がそれぞれCH2であり、L2およびL3がそれぞれNR 3である、請求項57記載の方法。
- 68.L2とL3が一緒になって、シクロプロピル、シクロブチル、エチレンオ キシ、エチルアジリジン、または置換エチルアジリジン環の一部を形成している 、請求項57記載の方法。
- 69.L2とL3が一緒になって、C3〜C6炭素環、または4,5,もしくは 6員構成の窒素複素環を形成している、請求項57記載の方法。
- 70.XがHである、請求項57記載の方法。
- 71.XがOHである、請求項57記載の方法。
- 72.XがH、OH、F、O−アルキル、またはO−アルケニルであり、かつ、 QがOである、請求項57記載の方法。
- 73.Bxが、アデニン、グアニン、ウラシル、チミン、シトシン、2−アミノ アデノシン、または5−メチルシトシンである、請求項57記載の方法。
- 74.QがOである、請求項73記載の方法。
- 75.L1およびL4がそれぞれCH2である、請求項74記載の方法。
- 76.L2およびL3がそれぞれNHである、請求項75記載の方法。
- 77.L2とL3の一方がOであり、L2とL33の他方がNHである、請求項 75記載の方法。
- 78.L2がNHであり、L3がOである、請求項75記載の方法。
- 79.L2がOであり、L3がNHである、請求項75記載の方法。
- 80.オリゴヌクレオチド類似体が前記の構造を有するサブユニットを約5〜5 0個含む、請求項57記載の方法。
- 81.オリゴヌクレオチド類似体の実質的にすべてのサブユニットが前記の構造 を有する、請求項57記載の方法。
- 82.オリゴヌクレオチド類似体の実質的に交互のサブユニットが前記の構造を 有する、請求項57記載の方法。
- 83.オリゴヌクレオチド類似体が医薬用として許容しうるキャリヤー中に含ま れる、請求項57記載の方法。
- 84.オリゴヌクレオチド類似体が対応する天然のオリゴヌクレオチドに比べて 、改良された耐ヌクレアーゼ性を示す、請求項57記載の方法。
- 85.請求項1記載のオリゴヌクレオチド類似体を合成する方法であって、次の 構造: ▲数式、化学式、表等があります▼ を含む第1の部分と、次の構造: ▲数式、化学式、表等があります▼ を含む第2の部分[式中、Bxは可変の塩基部分であり、QはO,CH2,CH F,またはCF2であり、そしてE1およびE2は同一または異なり、求電子反 応基である]を用意すること:および 前記第1と第2の部分を、前記求電子反応基を介して結合基とカップリングして 、前記オリゴヌクレオチド類似体を形成させること;を含む方法。
- 86.第1の部分の求電子反応基が、ハロメチル、トリフルオロメチル、スルホ ニルメチル、p−メチル−ベンゼンスルホニルメチルまたは3′−C−ホルミル を含む、請求項85記載の方法。
- 87.第2の部分の求電子反応基が、ハロゲン、スルホニルメチル、p−メチル ーベンゼンスルホニルメチルまたはアルデヒドを含む、請求項85記載の方法。
- 88.結合基が、ヒドラジンまたはヒドロキシルアミンである、請求項85記載 の方法。
- 89.前記オリゴヌクレオチド類似体の少なくとも−部を、別のオリゴヌクレオ チド化学種に組み込んで、天然のホスホジエステル結合とそのようにカップリン グされた区域が実質的に交互に存在する状態の前記別のオリゴヌクレオチド類似 体を得る、請求項85記載の方法。
- 90.該組み込みが、所望の配列を有するジヌクレオチドのホスホジエステル結 合によって達成され、ここで前記ジヌクレオチドはあらかじめそのようにカップ リングされている、請求項85記載の方法。
- 91.次の構造: ▲数式、化学式、表等があります▼ [式中、 Bxは可変の塩基部分であり: QはO,CH2,CHF,またはCF2であり;XはH,OH,C1〜C10低 級アルキル,置換低級アルキル,アルカリール,アラルキル,F,Cl,Br, CN,CF3,OCF3,OCN,O−アルキル,S−アルキル,N−アルキル ,O−アルケニル,S−アルケニル,N−アルケニル,SOCH3,SO2CH 3,ONO2,NO2,N3,NH2,ヘテロシクロアルキル,ヘテロシクロア ルカリール,アミノアルキルアミノ,ポリアルキルアミノ,置換シリル,RNA 開裂基,オリゴヌクレオチドの薬物動態学的特性を改良するための基,またはオ リゴヌクレオチドの薬力学的特性を改良するための基であり;Yはヒドロキシ、 アミノメチル、ヒドラジノメチル、ヒドロキシメチル、C−ホルミル、フタルイ ミドヒドロキシメチル、アリール置換イミダゾリジノ、アミノヒドロキシメチル 、オルト−メチルアミノベンゼンチオ、メチルホスホネート、またはメチルアル キルホスホネートであり;ZはH、ヒドロキシル、アミノメチル、ヒドラジノメ チル、ヒドロキシメチル、C−ホルミル、フタルイミドヒドロキシメチル、アリ ール置換イミダゾリジノ、アミノヒドロキシメチル、オルト−メチルアミノベン ゼンチオ、メチルホスホネート、またはメチルアルキルホスホネートであり;た だし、QがOであり、Yがヒドロキシメチルであり、かつXがHまたはOHであ るときは、ZはHまたはC−ホルミルではなく;またQがOであり、XがHまた はOHであり、かつZがヒドロキシルであるときは、Yはアミノヒドロキシメチ ル、ヒドラジノメチル、またはアリール置換イミダゾリジノではない]を有する ヌクレオシド。
- 92.XがHまたはOHである、請求項91記載のヌクレオシド。
- 93.QがOである、請求項91記載のヌクレオシド。
- 94.請求項1記載のオリゴヌクレオチド類似体を合成する方法であって、ペン トフラノシルヌクレオシドの3′炭素原子においてラジカルを生成させること; および 別のペントフラノシルヌクレオシドの5′位にペンダント状態になっているオキ シム部分と該ラジカルとを反応させること;を含む方法。
- 95.請求項1記載のオリゴヌクレオチド類似体のL2またはL3の窒素部分を 保護する方法であって、ここでL2とL3の一方はNR3であり、R3はHであ り、窒素部分をフェノキシアセチルクロライドでブロックすること;オリゴヌク レオチド類似体をさらに反応させて該オリゴヌクレオチドを変性すること; および水酸化アンモニウムで窒素部分を脱ブロックすること;を含む方法。
- 96.二官能のヌクレオシドまたはオリゴヌクレオチド類似体を保護する方法で あって、ここで二官能価のうちの一つはアルデヒドであり、アルデヒドとメトキ シアミンとを反応させてアルデヒドのオキシム誘導体を形成させること; ヌクレオシドまたはオリゴヌクレオチド類似体をさらに反応させて該ヌクレオシ ドまたはオリゴヌクレオチド類似体を修飾すること;および該オキシムをアセト アルデヒドと反応させてアルデヒドを再生させること;を含む方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US703,619 | 1991-05-21 | ||
US07/703,619 US5378825A (en) | 1990-07-27 | 1991-05-21 | Backbone modified oligonucleotide analogs |
PCT/US1992/004294 WO1992020822A1 (en) | 1991-05-21 | 1992-05-21 | Backbone modified oligonucleotide analogues |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH06504067A true JPH06504067A (ja) | 1994-05-12 |
JP2711180B2 JP2711180B2 (ja) | 1998-02-10 |
Family
ID=24826111
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP5500301A Expired - Fee Related JP2711180B2 (ja) | 1991-05-21 | 1992-05-21 | 主鎖修飾されたオリゴヌクレオチド類似体 |
JP5500305A Expired - Lifetime JP2625257B2 (ja) | 1991-05-21 | 1992-05-21 | 主鎖修飾されたオリゴヌクレオチド類似体 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP5500305A Expired - Lifetime JP2625257B2 (ja) | 1991-05-21 | 1992-05-21 | 主鎖修飾されたオリゴヌクレオチド類似体 |
Country Status (14)
Country | Link |
---|---|
US (1) | US5378825A (ja) |
EP (3) | EP0586570B1 (ja) |
JP (2) | JP2711180B2 (ja) |
KR (2) | KR0156945B1 (ja) |
AT (2) | ATE191933T1 (ja) |
AU (2) | AU662538B2 (ja) |
BR (2) | BR9206027A (ja) |
CA (2) | CA2103464A1 (ja) |
DE (2) | DE69231441T2 (ja) |
FI (2) | FI935114A (ja) |
HU (2) | HU221806B1 (ja) |
IE (2) | IE921850A1 (ja) |
NO (2) | NO308703B1 (ja) |
WO (2) | WO1992020822A1 (ja) |
Families Citing this family (584)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6444798B1 (en) * | 1988-06-06 | 2002-09-03 | Steven Albert Benner | Chimeras of sulfur-linked oligonucleotide analogs and DNA and RNA |
US6753423B1 (en) | 1990-01-11 | 2004-06-22 | Isis Pharmaceuticals, Inc. | Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals |
US6005087A (en) * | 1995-06-06 | 1999-12-21 | Isis Pharmaceuticals, Inc. | 2'-modified oligonucleotides |
US5681941A (en) * | 1990-01-11 | 1997-10-28 | Isis Pharmaceuticals, Inc. | Substituted purines and oligonucleotide cross-linking |
US5872232A (en) * | 1990-01-11 | 1999-02-16 | Isis Pharmaceuticals Inc. | 2'-O-modified oligonucleotides |
US5859221A (en) * | 1990-01-11 | 1999-01-12 | Isis Pharmaceuticals, Inc. | 2'-modified oligonucleotides |
US6783931B1 (en) | 1990-01-11 | 2004-08-31 | Isis Pharmaceuticals, Inc. | Amine-derivatized nucleosides and oligonucleosides |
US20040142899A1 (en) * | 1990-01-11 | 2004-07-22 | Isis Pharmaceuticals, Inc. | Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals |
US6339066B1 (en) | 1990-01-11 | 2002-01-15 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C |
US6358931B1 (en) | 1990-01-11 | 2002-03-19 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating RNA |
US6399754B1 (en) * | 1991-12-24 | 2002-06-04 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides |
US7037646B1 (en) | 1990-01-11 | 2006-05-02 | Isis Pharmaceuticals, Inc. | Amine-derivatized nucleosides and oligonucleosides |
US5998603A (en) * | 1994-09-29 | 1999-12-07 | Isis Pharmaceuticals, Inc. | 4'-desmethyl nucleoside analogs, and oligomers thereof |
US6121433A (en) * | 1990-07-27 | 2000-09-19 | Isis Pharmaceuticals, Inc. | Oligomeric compounds having nitrogen-containing linkages |
US5618704A (en) * | 1990-07-27 | 1997-04-08 | Isis Pharmacueticals, Inc. | Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling |
US5602240A (en) * | 1990-07-27 | 1997-02-11 | Ciba Geigy Ag. | Backbone modified oligonucleotide analogs |
US5541307A (en) * | 1990-07-27 | 1996-07-30 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs and solid phase synthesis thereof |
US5378825A (en) * | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
US5386023A (en) * | 1990-07-27 | 1995-01-31 | Isis Pharmaceuticals | Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling |
US5623070A (en) * | 1990-07-27 | 1997-04-22 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
US5610289A (en) * | 1990-07-27 | 1997-03-11 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogues |
HU217036B (hu) * | 1990-08-03 | 1999-11-29 | Sanofi | Eljárás génexpresszió gátlására alkalmas vegyületek előállítására |
US5789573A (en) * | 1990-08-14 | 1998-08-04 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2 |
US5596086A (en) * | 1990-09-20 | 1997-01-21 | Gilead Sciences, Inc. | Modified internucleoside linkages having one nitrogen and two carbon atoms |
US5965722A (en) * | 1991-05-21 | 1999-10-12 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ras gene with chimeric and alternating oligonucleotides |
US7015315B1 (en) | 1991-12-24 | 2006-03-21 | Isis Pharmaceuticals, Inc. | Gapped oligonucleotides |
US6335434B1 (en) | 1998-06-16 | 2002-01-01 | Isis Pharmaceuticals, Inc., | Nucleosidic and non-nucleosidic folate conjugates |
US8153602B1 (en) | 1991-11-19 | 2012-04-10 | Isis Pharmaceuticals, Inc. | Composition and methods for the pulmonary delivery of nucleic acids |
US5359044A (en) * | 1991-12-13 | 1994-10-25 | Isis Pharmaceuticals | Cyclobutyl oligonucleotide surrogates |
WO1993018052A1 (en) * | 1992-03-05 | 1993-09-16 | Isis Pharmaceuticals, Inc. | Covalently cross-linked oligonucleotides |
US5543507A (en) * | 1992-03-05 | 1996-08-06 | Isis Pharmaceuticals, Inc. | Covalently cross-linked oligonucleotides |
US6537973B1 (en) | 1992-03-16 | 2003-03-25 | Isis Pharmaceuticals, Inc. | Oligonucleotide inhibition of protein kinase C |
US6117847A (en) * | 1992-03-16 | 2000-09-12 | Isis Pharmaceuticals, Inc. | Oligonucleotides for enhanced modulation of protein kinase C expression |
GB9207380D0 (en) * | 1992-04-03 | 1992-05-13 | Ici Plc | Compounds |
US5434257A (en) * | 1992-06-01 | 1995-07-18 | Gilead Sciences, Inc. | Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages |
US5817781A (en) | 1992-06-01 | 1998-10-06 | Gilead Sciences, Inc. | Modified internucleoside linkages (II) |
JP2879973B2 (ja) * | 1992-06-24 | 1999-04-05 | アイシス・ファーマシューティカルス・インコーポレーテッド | ヘテロ原子によるオリゴヌクレオシド連結 |
HUT73335A (en) * | 1992-10-05 | 1996-07-29 | Isis Pharmaceuticals Inc | Antisense oligonucleotides and methods for inhibition of the human ras genes, methods for inhibition of tumour-cells proliferation and methods for detection of activated ras-genes |
US5985558A (en) * | 1997-04-14 | 1999-11-16 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos |
US20030013670A1 (en) * | 1992-10-05 | 2003-01-16 | Monia Brett P. | Antisense oligonucleotide inhibition of ras |
US5872242A (en) * | 1992-10-05 | 1999-02-16 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide inhibition of ras |
US6784290B1 (en) | 1992-10-05 | 2004-08-31 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide inhibition of ras |
WO1994022891A1 (en) * | 1993-03-31 | 1994-10-13 | Sterling Winthrop Inc. | Oligonucleotides with amide linkages replacing phosphodiester linkages |
JPH08508489A (ja) * | 1993-03-31 | 1996-09-10 | スターリング ウィンスロップ インコーポレイティド | 二官能価ヌクレオシド、それらのオリゴマーならびにそれらの製造方法及び使用方法 |
GB9311682D0 (en) * | 1993-06-05 | 1993-07-21 | Ciba Geigy Ag | Chemical compounds |
US6605708B1 (en) * | 1993-07-28 | 2003-08-12 | Hybridon, Inc. | Building blocks with carbamate internucleoside linkages and oligonucleotides derived therefrom |
ATE247128T1 (de) | 1993-09-03 | 2003-08-15 | Isis Pharmaceuticals Inc | Aminoderivatisierte nukleoside und oligonukleoside |
US6653458B1 (en) | 1993-09-03 | 2003-11-25 | Isis Pharmaceuticals, Inc. | Modified oligonucleotides |
JPH09508134A (ja) * | 1994-01-26 | 1997-08-19 | チバ−ガイギー アクチェンゲゼルシャフト | 変型オリゴヌクレオチド |
US5625050A (en) * | 1994-03-31 | 1997-04-29 | Amgen Inc. | Modified oligonucleotides and intermediates useful in nucleic acid therapeutics |
US6391636B1 (en) | 1994-05-31 | 2002-05-21 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
US5981731A (en) * | 1994-05-31 | 1999-11-09 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of B-raf gene expression |
AU3222795A (en) * | 1994-08-09 | 1996-03-07 | Ciba-Geigy Ag | Antitumor antisense oligonucleotides |
GB9417746D0 (en) * | 1994-09-03 | 1994-10-19 | Ciba Geigy Ag | Chemical compounds |
GB9417938D0 (en) * | 1994-09-06 | 1994-10-26 | Ciba Geigy Ag | Compounds |
US5681940A (en) * | 1994-11-02 | 1997-10-28 | Icn Pharmaceuticals | Sugar modified nucleosides and oligonucleotides |
EP0714907A1 (en) * | 1994-11-30 | 1996-06-05 | F. Hoffmann-La Roche Ag | Oligoribonucleotides with amide backbone |
US5807718A (en) | 1994-12-02 | 1998-09-15 | The Scripps Research Institute | Enzymatic DNA molecules |
US6207826B1 (en) | 1995-03-27 | 2001-03-27 | Isis Pharmaceuticals, Inc. | Macrocyclic compounds having nitrogen-containing linkages |
EP0817787A4 (en) * | 1995-03-27 | 2000-09-13 | Isis Pharmaceuticals Inc | NITROGEN MACROCYCLIC COMPOUNDS |
US6420549B1 (en) * | 1995-06-06 | 2002-07-16 | Isis Pharmaceuticals, Inc. | Oligonucleotide analogs having modified dimers |
WO1996040726A1 (en) | 1995-06-07 | 1996-12-19 | Genta Incorporated | Novel carbamate-based cationic lipids |
US6143749A (en) * | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
US5665721A (en) * | 1995-06-07 | 1997-09-09 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
US5855911A (en) * | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
GB9604669D0 (en) | 1996-03-05 | 1996-05-01 | Ciba Geigy Ag | Chemical compounds |
US5856099A (en) * | 1996-05-21 | 1999-01-05 | Isis Pharmaceuticals, Inc. | Antisense compositions and methods for modulating type I interleukin-1 receptor expression |
US7812149B2 (en) * | 1996-06-06 | 2010-10-12 | Isis Pharmaceuticals, Inc. | 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations |
US20050119470A1 (en) * | 1996-06-06 | 2005-06-02 | Muthiah Manoharan | Conjugated oligomeric compounds and their use in gene modulation |
US20040147022A1 (en) * | 1996-06-06 | 2004-07-29 | Baker Brenda F. | 2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations |
US20040203024A1 (en) * | 1996-06-06 | 2004-10-14 | Baker Brenda F. | Modified oligonucleotides for use in RNA interference |
US9096636B2 (en) * | 1996-06-06 | 2015-08-04 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
US20040161777A1 (en) * | 1996-06-06 | 2004-08-19 | Baker Brenda F. | Modified oligonucleotides for use in RNA interference |
US20050053976A1 (en) * | 1996-06-06 | 2005-03-10 | Baker Brenda F. | Chimeric oligomeric compounds and their use in gene modulation |
US20050042647A1 (en) * | 1996-06-06 | 2005-02-24 | Baker Brenda F. | Phosphorous-linked oligomeric compounds and their use in gene modulation |
US5898031A (en) * | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
US20070275921A1 (en) * | 1996-06-06 | 2007-11-29 | Isis Pharmaceuticals, Inc. | Oligomeric Compounds That Facilitate Risc Loading |
US20040266706A1 (en) * | 2002-11-05 | 2004-12-30 | Muthiah Manoharan | Cross-linked oligomeric compounds and their use in gene modulation |
GB9612600D0 (en) | 1996-06-13 | 1996-08-21 | Ciba Geigy Ag | Chemical compounds |
AU3340797A (en) * | 1996-06-28 | 1998-01-21 | Novartis Ag | Modified oligonucleotides |
US7309692B1 (en) * | 1996-07-08 | 2007-12-18 | Board Of Regents, The University Of Texas System | Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1 |
US6077954A (en) | 1996-08-01 | 2000-06-20 | Isis Pharmaceuticals, Inc. | Substituted heterocyclic compounds |
JP4211948B2 (ja) | 1996-08-02 | 2009-01-21 | ベーイーオー・メリュー | 標的核酸配列の増幅方法 |
US6111085A (en) | 1996-09-13 | 2000-08-29 | Isis Pharmaceuticals, Inc. | Carbamate-derivatized nucleosides and oligonucleosides |
US6977244B2 (en) * | 1996-10-04 | 2005-12-20 | Board Of Regents, The University Of Texas Systems | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
US5780241A (en) * | 1996-11-05 | 1998-07-14 | Isis Pharmaceuticals, Inc. | Complex chemical libraries |
US6077833A (en) * | 1996-12-31 | 2000-06-20 | Isis Pharmaceuticals, Inc. | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
US6319906B1 (en) | 1996-12-31 | 2001-11-20 | Isis Pharmaceuticals | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
US7235653B2 (en) | 1996-12-31 | 2007-06-26 | Isis Pharmaceuticals, Inc. | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
US6127533A (en) | 1997-02-14 | 2000-10-03 | Isis Pharmaceuticals, Inc. | 2'-O-aminooxy-modified oligonucleotides |
US6172209B1 (en) * | 1997-02-14 | 2001-01-09 | Isis Pharmaceuticals Inc. | Aminooxy-modified oligonucleotides and methods for making same |
US6639062B2 (en) * | 1997-02-14 | 2003-10-28 | Isis Pharmaceuticals, Inc. | Aminooxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom |
US6576752B1 (en) * | 1997-02-14 | 2003-06-10 | Isis Pharmaceuticals, Inc. | Aminooxy functionalized oligomers |
AU735522C (en) | 1997-04-29 | 2005-04-07 | Scripps Research Institute, The | Enzymatic dna molecules |
ATE321882T1 (de) | 1997-07-01 | 2006-04-15 | Isis Pharmaceuticals Inc | Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre |
US5877309A (en) * | 1997-08-13 | 1999-03-02 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides against JNK |
US6133246A (en) * | 1997-08-13 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide compositions and methods for the modulation of JNK proteins |
US6809193B2 (en) | 1997-08-13 | 2004-10-26 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide compositions and methods for the modulation of JNK proteins |
US20070149472A1 (en) * | 1997-08-13 | 2007-06-28 | Mckay Robert | Antisense oligonucleotide compositions and methods for the modulation of jnk proteins |
US6518017B1 (en) * | 1997-10-02 | 2003-02-11 | Oasis Biosciences Incorporated | Combinatorial antisense library |
US20030165888A1 (en) * | 2001-07-18 | 2003-09-04 | Brown Bob D. | Oligonucleotide probes and primers comprising universal bases for diagnostic purposes |
US7704962B1 (en) | 1997-10-03 | 2010-04-27 | Board Of Regents, The University Of Texas System | Small oligonucleotides with anti-tumor activity |
US7285288B1 (en) | 1997-10-03 | 2007-10-23 | Board Of Regents, The University Of Texas System | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
US6232463B1 (en) | 1997-10-09 | 2001-05-15 | Isis Pharmaceuticals, Inc. | Substituted purines and oligonucleotide cross-linking |
US5948902A (en) * | 1997-11-20 | 1999-09-07 | South Alabama Medical Science Foundation | Antisense oligonucleotides to human serine/threonine protein phosphatase genes |
US5968748A (en) * | 1998-03-26 | 1999-10-19 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of human HER-2 expression |
US20040186071A1 (en) * | 1998-04-13 | 2004-09-23 | Bennett C. Frank | Antisense modulation of CD40 expression |
US7321828B2 (en) * | 1998-04-13 | 2008-01-22 | Isis Pharmaceuticals, Inc. | System of components for preparing oligonucleotides |
AU753270B2 (en) * | 1998-05-21 | 2002-10-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for topical delivery of oligonucleotides |
CA2329130A1 (en) * | 1998-05-21 | 1999-11-25 | Isis Pharmaceuticals Inc. | Compositions and methods for non-parenteral delivery of oligonucleotides |
US6300319B1 (en) | 1998-06-16 | 2001-10-09 | Isis Pharmaceuticals, Inc. | Targeted oligonucleotide conjugates |
US6867294B1 (en) | 1998-07-14 | 2005-03-15 | Isis Pharmaceuticals, Inc. | Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages |
US6043352A (en) | 1998-08-07 | 2000-03-28 | Isis Pharmaceuticals, Inc. | 2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides |
US6673912B1 (en) | 1998-08-07 | 2004-01-06 | Isis Pharmaceuticals, Inc. | 2′-O-aminoethyloxyethyl-modified oligonucleotides |
US20040009938A1 (en) * | 1998-08-07 | 2004-01-15 | Muthiah Manoharan | Methods of enhancing renal uptake of oligonucleotides |
US6175004B1 (en) | 1998-09-01 | 2001-01-16 | Isis Pharmaceuticals, Inc. | Process for the synthesis of oligonucleotides incorporating 2-aminoadenosine |
US6077709A (en) | 1998-09-29 | 2000-06-20 | Isis Pharmaceuticals Inc. | Antisense modulation of Survivin expression |
US6069243A (en) * | 1998-10-06 | 2000-05-30 | Isis Pharmaceuticals, Inc. | Process for oligonucleotide synthesis |
US6667176B1 (en) | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
US6492111B1 (en) | 1998-11-25 | 2002-12-10 | Isis Pharmaceuticals, Inc. | In situ binary synthesis of biologically effective molecules |
US6087112A (en) * | 1998-12-30 | 2000-07-11 | Oligos Etc. Inc. | Arrays with modified oligonucleotide and polynucleotide compositions |
US20030180789A1 (en) * | 1998-12-30 | 2003-09-25 | Dale Roderic M.K. | Arrays with modified oligonucleotide and polynucleotide compositions |
US6403779B1 (en) | 1999-01-08 | 2002-06-11 | Isis Pharmaceuticals, Inc. | Regioselective synthesis of 2′-O-modified nucleosides |
US6399765B1 (en) | 1999-03-17 | 2002-06-04 | Isis Pharmaceuticals, Inc. | Methods for removing dimethoxytrityl groups from oligonucleotides |
AU3934000A (en) | 1999-03-18 | 2000-10-04 | United Therapeutics Corporation | Inhibitors of endothelin-1 synthesis |
US6235891B1 (en) | 1999-03-31 | 2001-05-22 | South Alabama Medical Science Foundation | Glucocorticoid receptor agonist and decreased PP5 |
US7098192B2 (en) | 1999-04-08 | 2006-08-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of STAT3 expression |
JP2002541825A (ja) * | 1999-04-08 | 2002-12-10 | オアシス バイオサイエンシーズ インコーポレイティッド | ユニバーサル及び/又は同義性塩基を含むアンチセンスオリゴヌクレオチド |
US6656730B1 (en) | 1999-06-15 | 2003-12-02 | Isis Pharmaceuticals, Inc. | Oligonucleotides conjugated to protein-binding drugs |
US6147200A (en) * | 1999-08-19 | 2000-11-14 | Isis Pharmaceuticals, Inc. | 2'-O-acetamido modified monomers and oligomers |
US6277982B1 (en) | 1999-08-20 | 2001-08-21 | Isis Pharmaceuticals, Inc. | Alkylation of alcohols, amines, thiols and their derivatives by cyclic sulfate intermediates |
US20020055479A1 (en) | 2000-01-18 | 2002-05-09 | Cowsert Lex M. | Antisense modulation of PTP1B expression |
US6261840B1 (en) | 2000-01-18 | 2001-07-17 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
CN1274072C (zh) * | 2000-08-03 | 2006-09-06 | 松下电器产业株式会社 | 无刷电机及其制造方法 |
US7767802B2 (en) | 2001-01-09 | 2010-08-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
AU2002315393A1 (en) | 2001-06-21 | 2003-01-08 | Isis Pharmaceuticals, Inc. | Antisense modulation of superoxide dismutase 1, soluble expression |
US6964950B2 (en) | 2001-07-25 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of C-reactive protein expression |
US7425545B2 (en) | 2001-07-25 | 2008-09-16 | Isis Pharmaceuticals, Inc. | Modulation of C-reactive protein expression |
US20030096772A1 (en) | 2001-07-30 | 2003-05-22 | Crooke Rosanne M. | Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression |
US7407943B2 (en) | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
US7227014B2 (en) | 2001-08-07 | 2007-06-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein (a) expression |
CA2457565A1 (en) | 2001-10-09 | 2003-04-17 | Genentech, Inc. | Novel acidic mammalian proteins and polynucleotides encoding the same |
NZ566396A (en) | 2001-10-09 | 2009-07-31 | Isis Pharmaceuticals Inc | Antisense modulation of insulin-like growth factor binding protein 5 expressions |
US6750019B2 (en) | 2001-10-09 | 2004-06-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of insulin-like growth factor binding protein 5 expression |
DE10159904A1 (de) * | 2001-12-06 | 2003-07-03 | Adnagen Ag | Oligonukleotidanordnung, Verfahren zum Nukleotidnachweis sowie Vorrichtung hierfür |
US6965025B2 (en) | 2001-12-10 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of connective tissue growth factor expression |
WO2003061386A1 (en) * | 2002-01-03 | 2003-07-31 | Board Of Regents, The University Of Texas System | Wt1 antisense oligos for the inhibition of breast cancer |
US20060009409A1 (en) | 2002-02-01 | 2006-01-12 | Woolf Tod M | Double-stranded oligonucleotides |
US20030166282A1 (en) * | 2002-02-01 | 2003-09-04 | David Brown | High potency siRNAS for reducing the expression of target genes |
ATE508188T1 (de) | 2002-02-01 | 2011-05-15 | Life Technologies Corp | Oligonukleotid-zusammensetzungen mit verbesserter wirksamkeit |
US20030191075A1 (en) * | 2002-02-22 | 2003-10-09 | Cook Phillip Dan | Method of using modified oligonucleotides for hepatic delivery |
US7169916B2 (en) * | 2002-04-01 | 2007-01-30 | Isis Pharmaceuticals, Inc. | Chloral-free DCA in oligonucleotide synthesis |
US7199107B2 (en) | 2002-05-23 | 2007-04-03 | Isis Pharmaceuticals, Inc. | Antisense modulation of kinesin-like 1 expression |
US20100075423A1 (en) * | 2002-06-12 | 2010-03-25 | Life Technologies Corporation | Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference |
US20040248094A1 (en) * | 2002-06-12 | 2004-12-09 | Ford Lance P. | Methods and compositions relating to labeled RNA molecules that reduce gene expression |
US20040106785A1 (en) * | 2002-07-25 | 2004-06-03 | Micrologix Biotech Inc. | Inhibitors of RNA dependent RNA polymerase and uses thereof |
EP3222726A1 (en) | 2002-08-05 | 2017-09-27 | Silence Therapeutics GmbH | Further novel forms of interfering rna molecules |
US20040029275A1 (en) * | 2002-08-10 | 2004-02-12 | David Brown | Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs |
US20050196382A1 (en) * | 2002-09-13 | 2005-09-08 | Replicor, Inc. | Antiviral oligonucleotides targeting viral families |
WO2004024919A1 (en) * | 2002-09-13 | 2004-03-25 | Replicor, Inc. | Non-sequence complementary antiviral oligonucleotides |
WO2004027030A2 (en) * | 2002-09-18 | 2004-04-01 | Isis Pharmaceuticals, Inc. | Efficient reduction of target rna’s by single- and double-stranded oligomeric compounds |
AU2003278957A1 (en) | 2002-09-26 | 2004-04-23 | Amgen, Inc. | Modulation of forkhead box o1a expression |
CA2504720C (en) | 2002-11-05 | 2013-12-24 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
AU2003290597A1 (en) * | 2002-11-05 | 2004-06-03 | Isis Pharmaceuticals, Inc. | Modified oligonucleotides for use in rna interference |
EP2336318B1 (en) | 2002-11-13 | 2013-04-24 | Genzyme Corporation | Antisense modulation of apolipoprotein b expression |
ES2417879T3 (es) | 2002-11-13 | 2013-08-09 | Genzyme Corporation | Modulación antisentido de la expresión de la apolipoproteína B |
US7144999B2 (en) | 2002-11-23 | 2006-12-05 | Isis Pharmaceuticals, Inc. | Modulation of hypoxia-inducible factor 1 alpha expression |
ES2400033T3 (es) | 2003-02-11 | 2013-04-05 | Antisense Therapeutics Ltd | Modulación de la expresión del receptor del factor de crecimiento I similar a la insulina |
US7002006B2 (en) * | 2003-02-12 | 2006-02-21 | Isis Pharmaceuticals, Inc. | Protection of nucleosides |
US7803781B2 (en) | 2003-02-28 | 2010-09-28 | Isis Pharmaceuticals, Inc. | Modulation of growth hormone receptor expression and insulin-like growth factor expression |
EP2216407B1 (en) | 2003-03-07 | 2016-01-13 | Alnylam Pharmaceuticals, Inc. | Therapeutic compositions |
US20040185559A1 (en) | 2003-03-21 | 2004-09-23 | Isis Pharmaceuticals Inc. | Modulation of diacylglycerol acyltransferase 1 expression |
US7598227B2 (en) | 2003-04-16 | 2009-10-06 | Isis Pharmaceuticals Inc. | Modulation of apolipoprotein C-III expression |
WO2004094595A2 (en) | 2003-04-17 | 2004-11-04 | Alnylam Pharmaceuticals Inc. | MODIFIED iRNA AGENTS |
US7399853B2 (en) | 2003-04-28 | 2008-07-15 | Isis Pharmaceuticals | Modulation of glucagon receptor expression |
US20040219533A1 (en) * | 2003-04-29 | 2004-11-04 | Jim Davis | Biological bar code |
US8679789B2 (en) * | 2003-05-01 | 2014-03-25 | Gen-Probe Incorporated | Oligonucleotides comprising a molecular switch |
US7897582B2 (en) | 2003-05-23 | 2011-03-01 | Isis Pharmaceuticals, Inc. | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
US7960355B2 (en) | 2003-05-23 | 2011-06-14 | Isis Pharmaceuticals, Inc. | Compositions and methods for the modulation of the expression of B7 protein |
WO2004108081A2 (en) * | 2003-06-02 | 2004-12-16 | Isis Pharmaceuticals, Inc. | Oligonucleotide synthesis with alternative solvents |
US7541344B2 (en) | 2003-06-03 | 2009-06-02 | Eli Lilly And Company | Modulation of survivin expression |
ES2905724T3 (es) | 2003-06-13 | 2022-04-11 | Alnylam Europe Ag | Acido ribonucleico bicatenario con elevada eficacia en un organismo |
US20060241072A1 (en) * | 2003-06-20 | 2006-10-26 | Isis Pharmaceuticals, Inc. | Oligomeric compounds for use in gene modulation |
WO2005017108A2 (en) * | 2003-06-30 | 2005-02-24 | United Soybean Board | Soybean selection system based on aec-resistance |
CA2533701A1 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
US7825235B2 (en) | 2003-08-18 | 2010-11-02 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
US20070123480A1 (en) * | 2003-09-11 | 2007-05-31 | Replicor Inc. | Oligonucleotides targeting prion diseases |
SG146682A1 (en) | 2003-09-18 | 2008-10-30 | Isis Pharmaceuticals Inc | Modulation of eif4e expression |
AU2004274021B2 (en) * | 2003-09-18 | 2009-08-13 | Isis Pharmaceuticals, Inc. | 4'-thionucleosides and oligomeric compounds |
US7125945B2 (en) * | 2003-09-19 | 2006-10-24 | Varian, Inc. | Functionalized polymer for oligonucleotide purification |
US20050191653A1 (en) | 2003-11-03 | 2005-09-01 | Freier Susan M. | Modulation of SGLT2 expression |
EP1711606A2 (en) | 2004-01-20 | 2006-10-18 | Isis Pharmaceuticals, Inc. | Modulation of glucocorticoid receptor expression |
US8569474B2 (en) * | 2004-03-09 | 2013-10-29 | Isis Pharmaceuticals, Inc. | Double stranded constructs comprising one or more short strands hybridized to a longer strand |
US20050244869A1 (en) * | 2004-04-05 | 2005-11-03 | Brown-Driver Vickie L | Modulation of transthyretin expression |
EP3034510A1 (en) | 2004-04-30 | 2016-06-22 | Alnylam Pharmaceuticals Inc. | Oligonucleotides comprising a c5-modified pyrimidine |
JP2008509226A (ja) | 2004-05-24 | 2008-03-27 | ジェンボールト コーポレイション | 回収可能な形式での安定なタンパク質保管および安定な核酸保管 |
EP2474616B1 (en) | 2004-05-28 | 2015-07-08 | Asuragen, Inc. | Methods and compositions involving microRNA |
EP1765416A4 (en) * | 2004-06-03 | 2010-03-24 | Isis Pharmaceuticals Inc | DOUBLE-STRANDED COMPOSITIONS COMPRISING DIFFERENTIALLY MODIFIED STRANDS FOR USE IN GENETIC MODULATION |
US8394947B2 (en) * | 2004-06-03 | 2013-03-12 | Isis Pharmaceuticals, Inc. | Positionally modified siRNA constructs |
US20090048192A1 (en) * | 2004-06-03 | 2009-02-19 | Isis Pharmaceuticals, Inc. | Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation |
CA2569036A1 (en) * | 2004-06-03 | 2005-12-22 | Balkrishen Bhat | Chimeric gapped oligomeric compositions |
US7968762B2 (en) * | 2004-07-13 | 2011-06-28 | Van Andel Research Institute | Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF) |
JP5192234B2 (ja) | 2004-08-10 | 2013-05-08 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | 化学修飾オリゴヌクレオチド |
BRPI0514395A (pt) | 2004-08-16 | 2008-06-10 | Quark Biotech Inc | uso terapêutico de inibidores de rtp801 |
DK1797183T3 (da) * | 2004-09-02 | 2012-10-01 | Univ Yale | Regulering af onkogener med mikrornas |
US7884086B2 (en) * | 2004-09-08 | 2011-02-08 | Isis Pharmaceuticals, Inc. | Conjugates for use in hepatocyte free uptake assays |
AU2005286738A1 (en) | 2004-09-17 | 2006-03-30 | Isis Pharmaceuticals, Inc. | Enhanced antisense oligonucleotides |
ES2503740T3 (es) | 2004-11-12 | 2014-10-07 | Asuragen, Inc. | Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN |
US8067175B2 (en) | 2005-02-11 | 2011-11-29 | Memorial Sloan-Kettering Cancer Center | Methods and compositions for detecting a drug resistant EGFR mutant |
US20060257902A1 (en) * | 2005-03-25 | 2006-11-16 | Ambion, Inc. | Methods and compositions for depleting abundant RNA transcripts |
EP1877418B1 (en) | 2005-05-06 | 2013-11-20 | Gen-Probe Incorporated | Compositions and assays to detect influenza virus a nucleic acids |
US8354384B2 (en) * | 2005-06-23 | 2013-01-15 | Yale University | Anti-aging micrornas |
US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
WO2007047912A2 (en) | 2005-10-17 | 2007-04-26 | Gen-Probe Incorporated | Compositions and methods to detect legionella pneumophila nucleic acid |
CA2627025A1 (en) * | 2005-10-28 | 2007-05-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of huntingtin gene |
AU2006311730B2 (en) | 2005-11-09 | 2010-12-02 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of Factor V Leiden mutant gene |
NL2000439C2 (nl) | 2006-01-20 | 2009-03-16 | Quark Biotech | Therapeutische toepassingen van inhibitoren van RTP801. |
PL2314594T3 (pl) | 2006-01-27 | 2014-12-31 | Isis Pharmaceuticals Inc | Zmodyfikowane w pozycji 6 analogi bicykliczne kwasów nukleinowych |
EP1987166A4 (en) | 2006-02-03 | 2010-06-02 | Univ Columbia | DEOXYRIBOZYME BINARY PROBES FOR ANALYSIS OF NUCLEIC ACID |
EP2511383B1 (en) | 2006-03-31 | 2013-12-25 | Columbia University | Binary probes for fluorescent analysis of nucleic acids |
DK2363481T3 (en) | 2006-05-05 | 2017-06-26 | Ionis Pharmaceuticals Inc | Compounds and methods for modulating gene expression |
US7666854B2 (en) * | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
KR101036126B1 (ko) | 2006-05-11 | 2011-05-23 | 알닐람 파마슈티칼스 인코포레이티드 | Pcsk9 유전자의 발현을 억제하기 위한 조성물 및 방법 |
JP5441688B2 (ja) * | 2006-05-11 | 2014-03-12 | アイシス ファーマシューティカルズ, インコーポレーテッド | 5’修飾二環式核酸類似体 |
ATE514794T1 (de) * | 2006-05-12 | 2011-07-15 | Gen Probe Inc | Zusammensetzungen und verfahren für den nachweis von enterokokken-nukleinsäuren |
EP2023938A4 (en) * | 2006-05-23 | 2010-11-10 | Isis Pharmaceuticals Inc | MODULATION OF THE EXPRESSION OF ChREBP |
WO2008011473A2 (en) | 2006-07-19 | 2008-01-24 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to hbxip |
CN102321626B (zh) | 2006-07-21 | 2014-12-10 | 赛伦斯治疗有限公司 | 用于抑制蛋白激酶3表达的方法 |
US9051601B2 (en) | 2006-08-01 | 2015-06-09 | Gen-Probe Incorporated | Methods of nonspecific target capture of nucleic acids |
US20090131348A1 (en) | 2006-09-19 | 2009-05-21 | Emmanuel Labourier | Micrornas differentially expressed in pancreatic diseases and uses thereof |
WO2008036776A2 (en) | 2006-09-19 | 2008-03-27 | Asuragen, Inc. | Mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention |
WO2008036933A2 (en) | 2006-09-21 | 2008-03-27 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the hamp gene |
CN110066224A (zh) | 2006-10-03 | 2019-07-30 | 阿尔尼拉姆医药品有限公司 | 含脂质的制品 |
JP2010507387A (ja) | 2006-10-25 | 2010-03-11 | クアーク・ファーマスーティカルス、インコーポレイテッド | 新規のsiRNAおよびその使用方法 |
US20100062436A1 (en) | 2006-10-31 | 2010-03-11 | Noxxon Pharma Ag | Methods for Detection of a Single- or Double-Stranded Nucleic Acid Molecule |
AU2007333109A1 (en) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Functions and targets of let-7 micro RNAs |
JP5340167B2 (ja) | 2006-12-21 | 2013-11-13 | ジェン−プロウブ インコーポレイテッド | 核酸増幅のための方法および組成物 |
EP2641971A1 (en) | 2007-01-29 | 2013-09-25 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating protein expression |
PE20090064A1 (es) | 2007-03-26 | 2009-03-02 | Novartis Ag | Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende |
WO2008140449A1 (en) | 2007-05-11 | 2008-11-20 | Thomas Jefferson University | Methods of treatment and prevention of neurodegenerative diseases and disorders |
EA018101B1 (ru) * | 2007-05-11 | 2013-05-30 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Способы лечения кожных язв |
EP2170917B1 (en) | 2007-05-30 | 2012-06-27 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
ES2386492T3 (es) | 2007-06-08 | 2012-08-21 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos carbocíclicos |
CA2691364C (en) | 2007-06-19 | 2020-06-16 | Stratos Genomics, Inc. | High throughput nucleic acid sequencing by expansion |
CN101688206B (zh) | 2007-07-05 | 2013-05-15 | 诺瓦提斯公司 | 用于治疗病毒感染的dsRNA |
US8278283B2 (en) * | 2007-07-05 | 2012-10-02 | Isis Pharmaceuticals, Inc. | 6-disubstituted or unsaturated bicyclic nucleic acid analogs |
ES2439591T3 (es) * | 2007-08-15 | 2014-01-23 | Isis Pharmaceuticals, Inc. | Análogos de ácido nucleico de tetrahidropirano |
EP2205741A2 (en) | 2007-10-02 | 2010-07-14 | Amgen Inc. | Increasing erythropoietin using nucleic acids hybridizable to micro-rna and precursors thereof |
CN103898110A (zh) | 2007-10-03 | 2014-07-02 | 夸克制药公司 | 新siRNA结构 |
WO2009067243A2 (en) | 2007-11-20 | 2009-05-28 | Isis Pharmaceuticals Inc. | Modulation of cd40 expression |
EP4074344A1 (en) | 2007-12-04 | 2022-10-19 | Arbutus Biopharma Corporation | Targeting lipids |
US7595164B2 (en) * | 2007-12-26 | 2009-09-29 | Gen-Probe Incorporated | Compositions and methods to detect Candida albicans nucleic acid |
US9605035B2 (en) | 2008-01-10 | 2017-03-28 | Research Development Foundation | Vaccines and diagnostics for the ehrlichioses |
WO2009100320A2 (en) * | 2008-02-07 | 2009-08-13 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexitol nucleic acid analogs |
AU2009222056A1 (en) * | 2008-03-01 | 2009-09-11 | Abraxis Bioscience, Llc | Treatment, diagnostic, and method for discovering antagonist using SPARC specific miRNAs |
EP2282744B1 (en) | 2008-03-21 | 2018-01-17 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising tricyclic nucleosides and methods for their use |
DK2285819T3 (da) * | 2008-04-04 | 2013-12-02 | Isis Pharmaceuticals Inc | Oligomere forbindelser omfattende neutralt bundne, terminale bicykliske nukleosider |
EP2274423A2 (en) * | 2008-04-04 | 2011-01-19 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity |
CA3044980A1 (en) | 2008-04-11 | 2009-10-15 | Alnylam Pharmaceuticals, Inc. | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
WO2009137660A2 (en) * | 2008-05-07 | 2009-11-12 | Abraxis Bioscience, Llc | Enhancement of drug therapy by mirna |
EP2285960B1 (en) | 2008-05-08 | 2015-07-08 | Asuragen, INC. | Compositions and methods related to mir-184 modulation of neovascularization or angiogenesis |
US20100209957A1 (en) * | 2008-06-20 | 2010-08-19 | Genvault Corporation | Biosample storage devices and methods of use thereof |
EP2323667A4 (en) * | 2008-08-07 | 2012-07-25 | Isis Pharmaceuticals Inc | MODULATION OF TRANSTHYRETIN EXPRESSION BY TREATMENT OF CNS DISEASES |
WO2010031007A2 (en) * | 2008-09-12 | 2010-03-18 | Genvault Corporation | Matrices and media for storage and stabilization of biomolecules |
JP2012513953A (ja) | 2008-09-23 | 2012-06-21 | アルニラム ファーマスーティカルズ インコーポレイテッド | 付加環化を用いたモノマーおよびオリゴヌクレオチドの化学修飾 |
DK2356129T3 (da) * | 2008-09-24 | 2013-05-13 | Isis Pharmaceuticals Inc | Substituerede alpha-L-bicykliske nukleosider |
US8604192B2 (en) * | 2008-09-24 | 2013-12-10 | Isis Pharmaceuticals, Inc. | Cyclohexenyl nucleic acids analogs |
EP2379084B1 (en) | 2008-10-15 | 2017-11-22 | Ionis Pharmaceuticals, Inc. | Modulation of factor 11 expression |
WO2010048549A2 (en) | 2008-10-24 | 2010-04-29 | Isis Pharmaceuticals, Inc. | 5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom |
WO2010048585A2 (en) | 2008-10-24 | 2010-04-29 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and methods |
CA2743057C (en) | 2008-11-07 | 2019-11-26 | Research Development Foundation | Compositions and methods for the inhibition of cripto/grp78 complex formation and signaling |
EA037404B1 (ru) | 2008-11-10 | 2021-03-24 | Арбутус Биофарма Корпорэйшн | Липиды и композиции для доставки лекарственных средств |
WO2010059944A1 (en) | 2008-11-21 | 2010-05-27 | Columbia University | A split dna enzyme for visual single nucleotide polymorphism typing |
RU2015151857A (ru) | 2008-12-02 | 2019-01-15 | Уэйв Лайф Сайенсес Джапан, Инк. | Способ синтеза модифицированных по атому фосфора нуклеиновых кислот |
WO2010080452A2 (en) | 2008-12-18 | 2010-07-15 | Quark Pharmaceuticals, Inc. | siRNA COMPOUNDS AND METHODS OF USE THEREOF |
US8853134B2 (en) | 2009-01-28 | 2014-10-07 | The Trustees Of Columbia University In The City Of New York | Microarrays of binary nucleic acid probes for detecting nucleic acid analytes |
US8536320B2 (en) | 2009-02-06 | 2013-09-17 | Isis Pharmaceuticals, Inc. | Tetrahydropyran nucleic acid analogs |
WO2010091308A2 (en) | 2009-02-06 | 2010-08-12 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and methods |
WO2010091878A2 (en) | 2009-02-13 | 2010-08-19 | Silence Therapeutics Ag | Means for inhibiting the expression of opa1 |
WO2010094491A1 (en) | 2009-02-18 | 2010-08-26 | Silence Therapeutics Ag | Means for inhibiting the expression of ang2 |
EP3424939A1 (en) | 2009-03-02 | 2019-01-09 | Alnylam Pharmaceuticals Inc. | Nucleic acid chemical modifications |
EP2408306A4 (en) * | 2009-03-20 | 2012-11-07 | Alios Biopharma Inc | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGUES |
US20110045080A1 (en) * | 2009-03-24 | 2011-02-24 | William Marsh Rice University | Single-Walled Carbon Nanotube/Bioactive Substance Complexes and Methods Related Thereto |
EP2258858A1 (en) | 2009-06-05 | 2010-12-08 | Universitätsklinikum Freiburg | Transgenic LSD1 animal model for cancer |
NZ712719A (en) | 2009-06-10 | 2017-03-31 | Arbutus Biopharma Corp | Improved lipid formulation |
US9169512B2 (en) | 2009-07-01 | 2015-10-27 | Gen-Probe Incorporated | Methods and compositions for nucleic acid amplification |
WO2011005761A1 (en) | 2009-07-06 | 2011-01-13 | Ontorii, Inc | Novel nucleic acid prodrugs and methods use thereof |
US8927513B2 (en) | 2009-07-07 | 2015-01-06 | Alnylam Pharmaceuticals, Inc. | 5′ phosphate mimics |
US9512164B2 (en) | 2009-07-07 | 2016-12-06 | Alnylam Pharmaceuticals, Inc. | Oligonucleotide end caps |
EP2462153B1 (en) | 2009-08-06 | 2015-07-29 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
WO2011020023A2 (en) | 2009-08-14 | 2011-02-17 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus |
TW201124160A (en) | 2009-11-26 | 2011-07-16 | Quark Pharmaceuticals Inc | SiRNA compounds comprising terminal substitutions |
CA2783372C (en) | 2009-12-07 | 2019-07-16 | Muthiah Manoharan | Compositions for nucleic acid delivery |
WO2011072091A1 (en) | 2009-12-09 | 2011-06-16 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the cns |
AU2010328104B2 (en) | 2009-12-09 | 2014-10-30 | Nitto Denko Corporation | Modulation of hsp47 expression |
WO2011075656A1 (en) | 2009-12-18 | 2011-06-23 | The University Of British Columbia | Methods and compositions for delivery of nucleic acids |
WO2011084193A1 (en) | 2010-01-07 | 2011-07-14 | Quark Pharmaceuticals, Inc. | Oligonucleotide compounds comprising non-nucleotide overhangs |
WO2011085102A1 (en) | 2010-01-11 | 2011-07-14 | Isis Pharmaceuticals, Inc. | Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom |
WO2011100131A2 (en) | 2010-01-28 | 2011-08-18 | Alnylam Pharmacuticals, Inc. | Monomers and oligonucleotides comprising cycloaddition adduct(s) |
WO2011094580A2 (en) | 2010-01-28 | 2011-08-04 | Alnylam Pharmaceuticals, Inc. | Chelated copper for use in the preparation of conjugated oligonucleotides |
WO2011103274A1 (en) | 2010-02-17 | 2011-08-25 | Gen-Probe Incorporated | Compositions and methods to detect atopobium vaginae nucleic acid |
WO2011108930A1 (en) | 2010-03-04 | 2011-09-09 | Interna Technologies Bv | A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS DIAGNOSTIC AND THERAPEUTIC USES IN DISEASES OR CONDITIONS ASSOCIATED WITH EMT |
WO2011115818A1 (en) | 2010-03-17 | 2011-09-22 | Isis Pharmaceuticals, Inc. | 5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom |
US9102938B2 (en) | 2010-04-01 | 2015-08-11 | Alnylam Pharmaceuticals, Inc. | 2′ and 5′ modified monomers and oligonucleotides |
EP3037555B1 (en) | 2010-04-21 | 2019-07-24 | Gen-Probe Incorporated | Compositions, methods and kits to detect herpes simplex virus nucleic acids |
WO2011133871A2 (en) | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | 5'-end derivatives |
US20130260460A1 (en) | 2010-04-22 | 2013-10-03 | Isis Pharmaceuticals Inc | Conformationally restricted dinucleotide monomers and oligonucleotides |
US10913767B2 (en) | 2010-04-22 | 2021-02-09 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising acyclic and abasic nucleosides and analogs |
WO2011139695A2 (en) | 2010-04-28 | 2011-11-10 | Isis Pharmaceuticals, Inc. | Modified 5' diphosphate nucleosides and oligomeric compounds prepared therefrom |
EP3091027B1 (en) | 2010-04-28 | 2018-01-17 | Ionis Pharmaceuticals, Inc. | 5' modified nucleosides and oligomeric compounds prepared therefrom |
EP3173419A1 (en) | 2010-04-28 | 2017-05-31 | Ionis Pharmaceuticals, Inc. | Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom |
EP2563920B1 (en) | 2010-04-29 | 2017-03-15 | Ionis Pharmaceuticals, Inc. | Modulation of transthyretin expression |
WO2011139911A2 (en) | 2010-04-29 | 2011-11-10 | Isis Pharmaceuticals, Inc. | Lipid formulated single stranded rna |
BR112012031363A2 (pt) | 2010-05-28 | 2021-10-26 | Sarepta Therapeutcs, Inc | Análogos de oligonucleotídeo tendo ligações intersubunidades modificadas e/ou grupos terminais. |
WO2011156278A1 (en) | 2010-06-07 | 2011-12-15 | Isis Pharmaceuticals, Inc. | Bicyclic nucleosides and oligomeric compounds prepared therefrom |
EP2580228B1 (en) | 2010-06-08 | 2016-03-23 | Ionis Pharmaceuticals, Inc. | Substituted 2'-amino and 2'-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
CN103097534B (zh) | 2010-06-24 | 2017-07-28 | 夸克制药公司 | 针对rhoa的双链rna化合物及其用途 |
EP2588629B1 (en) | 2010-06-30 | 2017-05-17 | Gen-Probe Incorporated | Method and apparatus for identifying analyte-containing samples using single-read determination of analyte and process control signals |
NZ704322A (en) | 2010-07-06 | 2016-07-29 | Interna Technologies Bv | Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway |
WO2012009373A2 (en) | 2010-07-12 | 2012-01-19 | Gen-Probe Incorporated | Compositions and assays to detect swine h1n1 influenza a virus, seasonal h1 influenza a virus and seasonal h3 influenza a virus nucleic acids |
WO2012016184A2 (en) | 2010-07-30 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
WO2012016188A2 (en) | 2010-07-30 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
CN103328500B (zh) | 2010-08-04 | 2018-01-26 | 西兹尔生物技术有限公司 | 用于癌症的诊断和治疗的方法和化合物 |
WO2012030856A2 (en) | 2010-08-30 | 2012-03-08 | Gen-Probe Incorporated | Compositions, methods and reaction mixtures for the detection of xenotropic murine leukemia virus-related virus |
US10017763B2 (en) | 2010-09-03 | 2018-07-10 | Sarepta Therapeutics, Inc. | dsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups |
US9938590B2 (en) | 2010-09-16 | 2018-04-10 | Gen-Probe Incorporated | Capture probes immobilizable via L-nucleotide tail |
KR20130110170A (ko) | 2010-09-22 | 2013-10-08 | 앨리오스 바이오파마 인크. | 치환된 뉴클레오타이드 유사체 |
EP2620428B1 (en) | 2010-09-24 | 2019-05-22 | Wave Life Sciences Ltd. | Asymmetric auxiliary group |
GB2497495B (en) | 2010-10-04 | 2018-06-06 | Gen Probe Prodesse Inc | Compositions, methods and kits to detect adenovirus nucleic acids |
US20140134231A1 (en) | 2010-10-11 | 2014-05-15 | Sanford-Burnham Medical Research Institute | Mir-211 expression and related pathways in human melanoma |
EP2635703B1 (en) | 2010-11-01 | 2018-03-21 | Gen-Probe Incorporated | Integrated capture and amplification of target nucleic acid for sequencing |
US8569220B2 (en) | 2010-11-12 | 2013-10-29 | Jelmar, Llc | Hard surface cleaning composition |
EP2640853B1 (en) | 2010-11-17 | 2018-12-26 | Ionis Pharmaceuticals, Inc. | Modulation of alpha synuclein expression |
EP2649181B1 (en) | 2010-12-06 | 2016-04-27 | Quark Pharmaceuticals, Inc. | Double stranded oligonucleotide compounds comprising positional modifications |
EP2474617A1 (en) | 2011-01-11 | 2012-07-11 | InteRNA Technologies BV | Mir for treating neo-angiogenesis |
EP3202760B1 (en) | 2011-01-11 | 2019-08-21 | Alnylam Pharmaceuticals, Inc. | Pegylated lipids and their use for drug delivery |
JP6132775B2 (ja) | 2011-03-03 | 2017-05-24 | クォーク ファーマシューティカルズ インコーポレーティッドQuark Pharmaceuticals,Inc. | Toll様受容体経路のオリゴヌクレオチド修飾因子 |
SG192961A1 (en) | 2011-03-03 | 2013-09-30 | Quark Pharmaceuticals Inc | Compositions and methods for treating lung disease and injury |
USRE49975E1 (en) | 2011-03-10 | 2024-05-21 | Gen-Probe Incorporated | Methods and compositions for the selection and optimization of oligonucleotide tag sequences |
US9657352B2 (en) | 2011-04-25 | 2017-05-23 | Gen-Probe Incorporated | Compositions and methods for detecting BV-associated bacterial nucleic acid |
TWI658830B (zh) | 2011-06-08 | 2019-05-11 | 日東電工股份有限公司 | Hsp47表現調控強化用類視色素脂質體 |
US10196637B2 (en) | 2011-06-08 | 2019-02-05 | Nitto Denko Corporation | Retinoid-lipid drug carrier |
WO2012170347A1 (en) | 2011-06-09 | 2012-12-13 | Isis Pharmaceuticals, Inc. | Bicyclic nucleosides and oligomeric compounds prepared therefrom |
US20140227293A1 (en) | 2011-06-30 | 2014-08-14 | Trustees Of Boston University | Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1) |
CN113215308A (zh) | 2011-07-15 | 2021-08-06 | 简.探针公司 | 检测人细小病毒核酸和甲型肝炎病毒核酸的组合物和方法 |
MX347361B (es) | 2011-07-19 | 2017-04-12 | Wave Life Sciences Ltd | Metodos para la sintesis de acidos nucleicos funcionalizados. |
EP4269584A3 (en) | 2011-08-11 | 2024-03-27 | Ionis Pharmaceuticals, Inc. | Selective antisense compounds and uses thereof |
EP3640332A1 (en) | 2011-08-29 | 2020-04-22 | Ionis Pharmaceuticals, Inc. | Oligomer-conjugate complexes and their use |
EP3225698B1 (en) | 2011-09-06 | 2019-07-31 | Gen-Probe Incorporated | Closed nucleic acid structures |
AU2012304520B2 (en) | 2011-09-06 | 2016-06-16 | Gen-Probe Incorporated | Circularized templates for sequencing |
US9663829B2 (en) | 2011-09-08 | 2017-05-30 | Gen-Probe Incorporated | Compositions and methods for detecting BV-associated bacterial nucleic acid |
US9644241B2 (en) | 2011-09-13 | 2017-05-09 | Interpace Diagnostics, Llc | Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease |
AU2012315965A1 (en) | 2011-09-27 | 2014-04-03 | Alnylam Pharmaceuticals, Inc. | Di-aliphatic substituted PEGylated lipids |
WO2013063519A1 (en) | 2011-10-26 | 2013-05-02 | Asuragen, Inc. | Methods and compositions involving mirna expression levels for distinguishing pancreatic cysts |
CA2851296C (en) | 2011-11-03 | 2020-08-25 | Quark Pharmaceuticals, Inc. | Methods and compositions for neuroprotection |
US9863004B2 (en) | 2011-11-04 | 2018-01-09 | Gen-Probe Incorporated | Molecular assay reagents and methods |
US20140323549A1 (en) | 2011-11-08 | 2014-10-30 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the nervous system |
AU2012340390B2 (en) | 2011-11-18 | 2016-11-24 | Sarepta Therapeutics, Inc. | Functionally-modified oligonucleotides and subunits thereof |
DE102011120550B4 (de) | 2011-12-05 | 2013-11-07 | Gen-Probe Prodesse, Inc. | Zusammensetzungen, Verfahren und Kits zur Detektion von Adenovirusnukleinsäuren |
US8980865B2 (en) | 2011-12-22 | 2015-03-17 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
LT2794627T (lt) | 2011-12-22 | 2019-01-10 | Alios Biopharma, Inc. | Pakeistieji nukleozidai, nukleotidai ir jų analogai |
EP2794881B1 (en) | 2011-12-22 | 2018-06-27 | InteRNA Technologies B.V. | Mirna for treating head and neck cancer |
CA2858336A1 (en) | 2012-01-01 | 2013-07-04 | Qbi Enterprises Ltd. | Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents |
AU2013208012A1 (en) | 2012-01-12 | 2014-07-03 | Quark Pharmaceuticals, Inc. | Combination therapy for treating hearing and balance disorders |
AU2013205603B2 (en) | 2012-02-01 | 2016-03-17 | Gen-Probe Incorporated | Asymmetric hairpin target capture oligomers |
WO2013123996A1 (en) | 2012-02-24 | 2013-08-29 | Astrazeneca Uk Limited | Novel sirna inhibitors of human icam-1 |
BR112014022195A2 (pt) | 2012-03-09 | 2020-05-12 | Vestaron Corporation | Produção de peptídeo tóxico, expressão de peptídeo em plantas e combinações de peptídeos ricos em cisteína |
EP2639238A1 (en) | 2012-03-15 | 2013-09-18 | Universität Bern | Tricyclic nucleosides and oligomeric compounds prepared therefrom |
CN104321333A (zh) | 2012-03-21 | 2015-01-28 | 沃泰克斯药物股份有限公司 | 硫代氨基磷酸酯核苷酸前药的固体形式 |
USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
NZ630805A (en) | 2012-03-22 | 2016-01-29 | Alios Biopharma Inc | Pharmaceutical combinations comprising a thionucleotide analog |
WO2013154799A1 (en) | 2012-04-09 | 2013-10-17 | Isis Pharmaceuticals, Inc. | Tricyclic nucleosides and oligomeric compounds prepared therefrom |
US9221864B2 (en) | 2012-04-09 | 2015-12-29 | Isis Pharmaceuticals, Inc. | Tricyclic nucleic acid analogs |
AU2013205110B2 (en) | 2012-04-24 | 2016-10-13 | Gen-Probe Incorporated | Compositions, Methods and Kits to Detect Herpes Simplex Virus Nucleic Acids |
WO2013179289A1 (en) | 2012-05-31 | 2013-12-05 | Bio-Lab Ltd. | Pyrazolotriazolyl nucleoside analogues and oligonucleotides comprising them |
AU2013205064B2 (en) | 2012-06-04 | 2015-07-30 | Gen-Probe Incorporated | Compositions and Methods for Amplifying and Characterizing HCV Nucleic Acid |
CA2879023C (en) | 2012-07-13 | 2017-03-28 | Wave Life Sciences Japan | Asymmetric auxiliary group |
AU2013205087B2 (en) | 2012-07-13 | 2016-03-03 | Gen-Probe Incorporated | Method for detecting a minority genotype |
AU2013202793B2 (en) | 2012-07-31 | 2014-09-18 | Gen-Probe Incorporated | System, method and apparatus for automated incubation |
ES2761920T3 (es) | 2012-08-30 | 2020-05-21 | Gen Probe Inc | Amplificación de ácido nucleico multifásica |
DK2895608T3 (en) | 2012-09-12 | 2019-01-21 | Quark Pharmaceuticals Inc | DOUBLE-STRENGTHED OIGONUCLEOTIDE MOLECULES FOR P53 AND PROCEDURES FOR USING IT |
EP2895607B1 (en) | 2012-09-12 | 2021-05-05 | Quark Pharmaceuticals, Inc. | Double-stranded oligonucleotide molecules to ddit4 and methods of use thereof |
US9611473B2 (en) | 2012-09-12 | 2017-04-04 | Quark Pharmaceuticals, Inc. | Double-stranded nucleic acid compounds |
US9993522B2 (en) | 2012-09-18 | 2018-06-12 | Uti Limited Partnership | Treatment of pain by inhibition of USP5 de-ubiquitinase |
US20140100124A1 (en) | 2012-10-04 | 2014-04-10 | Asuragen, Inc. | Diagnostic mirnas for differential diagnosis of incidental pancreatic cystic lesions |
AU2013205122B2 (en) | 2012-10-11 | 2016-11-10 | Gen-Probe Incorporated | Compositions and Methods for Detecting Human Papillomavirus Nucleic Acid |
US9029335B2 (en) | 2012-10-16 | 2015-05-12 | Isis Pharmaceuticals, Inc. | Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
WO2014072357A1 (en) | 2012-11-06 | 2014-05-15 | Interna Technologies B.V. | Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated b-raf pathway |
AU2013205090B2 (en) | 2012-12-07 | 2016-07-28 | Gen-Probe Incorporated | Compositions and Methods for Detecting Gastrointestinal Pathogen Nucleic Acid |
EP2961853B1 (en) | 2013-02-28 | 2018-09-19 | The Board of Regents of The University of Texas System | Methods for classifying a cancer as susceptible to tmepai-directed therapies and treating such cancers |
US10174352B2 (en) | 2013-03-14 | 2019-01-08 | Aegea Biotechnologies, Inc. | Methods for amplification of nucleic acids on solid support |
WO2014145176A1 (en) | 2013-03-15 | 2014-09-18 | Arnold Lyle J | Methods for amplifying fragmented target nucleic acids utilizing an assembler sequence |
WO2014145138A2 (en) | 2013-03-15 | 2014-09-18 | Arnold Lyle J | Methods for amplification of nucleic acids utilizing clamp oligonuleotides |
EP4163387A1 (en) | 2013-03-15 | 2023-04-12 | The University of Chicago | Methods and compositions related to t-cell activity |
US9937231B2 (en) | 2013-03-27 | 2018-04-10 | The General Hospital Corporation | Methods and agents for treating Alzheimer's disease |
WO2014179625A1 (en) | 2013-05-01 | 2014-11-06 | Isis Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION |
WO2015015498A1 (en) | 2013-07-31 | 2015-02-05 | Qbi Enterprises Ltd. | Methods of use of sphingolipid polyalkylamine oligonucleotide compounds |
US9889200B2 (en) | 2013-07-31 | 2018-02-13 | Qbi Enterprises Ltd. | Sphingolipid-polyalkylamine-oligonucleotide compounds |
US10053742B2 (en) | 2013-08-14 | 2018-08-21 | Gen-Probe Incorporated | Compositions and methods for detecting HEV nucleic acid |
EP2853595A1 (en) | 2013-09-30 | 2015-04-01 | Soluventis GmbH | NOTCH 1 specific siRNA molecules |
US11162096B2 (en) | 2013-10-14 | 2021-11-02 | Ionis Pharmaceuticals, Inc | Methods for modulating expression of C9ORF72 antisense transcript |
EP3065706A4 (en) | 2013-11-08 | 2017-11-29 | Baylor Research Institute | Nuclear localization of glp-1 stimulates myocardial regeneration and reverses heart failure |
ES2797679T3 (es) | 2013-12-02 | 2020-12-03 | Ionis Pharmaceuticals Inc | Compuestos antisentido y usos de los mismos |
EP4137572A1 (en) | 2014-01-16 | 2023-02-22 | Wave Life Sciences Ltd. | Chiral design |
WO2015123551A1 (en) | 2014-02-13 | 2015-08-20 | Du Luqin | Microrna composition for the treatment of neuroblastoma |
US10036019B2 (en) | 2014-03-17 | 2018-07-31 | Ionis Pharmaceuticals, Inc. | Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom |
EP3119888B1 (en) | 2014-03-19 | 2021-07-28 | Ionis Pharmaceuticals, Inc. | Compositions for modulating ataxin 2 expression |
WO2015143245A1 (en) | 2014-03-19 | 2015-09-24 | Isis Pharmaceuticals, Inc. | Methods for modulating ataxin 2 expression |
PL3126499T3 (pl) | 2014-04-01 | 2020-11-30 | Biogen Ma Inc. | Kompozycje do modulowania ekspresji sod-1 |
WO2015164693A1 (en) | 2014-04-24 | 2015-10-29 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising alpha-beta-constrained nucleic acid |
WO2015168172A1 (en) | 2014-04-28 | 2015-11-05 | Isis Pharmaceuticals, Inc. | Linkage modified oligomeric compounds |
AU2015252858C1 (en) | 2014-05-01 | 2021-09-16 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating Complement Factor B expression |
CA2946003A1 (en) | 2014-05-01 | 2015-11-05 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating angiopoietin-like 3 expression |
WO2015190922A1 (en) | 2014-06-10 | 2015-12-17 | Erasmus University Medical Center Rotterdam | Antisense oligonucleotides useful in treatment of pompe disease |
WO2016033424A1 (en) | 2014-08-29 | 2016-03-03 | Genzyme Corporation | Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b |
WO2016044271A2 (en) | 2014-09-15 | 2016-03-24 | Children's Medical Center Corporation | Methods and compositions to increase somatic cell nuclear transfer (scnt) efficiency by removing histone h3-lysine trimethylation |
WO2016057693A1 (en) | 2014-10-10 | 2016-04-14 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for inhalation delivery of conjugated oligonucleotide |
JP6767374B2 (ja) | 2014-10-20 | 2020-10-14 | ジェン−プローブ・インコーポレーテッド | 赤血球溶解溶液 |
WO2016083624A1 (en) | 2014-11-28 | 2016-06-02 | Silence Therapeutics Gmbh | Means for inhibiting the expression of edn1 |
WO2016094845A2 (en) | 2014-12-12 | 2016-06-16 | Woolf Tod M | Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides |
WO2016100716A1 (en) | 2014-12-18 | 2016-06-23 | Vasant Jadhav | Reversirtm compounds |
US9688707B2 (en) | 2014-12-30 | 2017-06-27 | Ionis Pharmaceuticals, Inc. | Bicyclic morpholino compounds and oligomeric compounds prepared therefrom |
US10793855B2 (en) | 2015-01-06 | 2020-10-06 | Ionis Pharmaceuticals, Inc. | Compositions for modulating expression of C9ORF72 antisense transcript |
EP3242956B1 (en) | 2015-01-09 | 2020-06-17 | Gen-Probe Incorporated | Methods and compositions for diagnosing bacterial vaginosis |
US10538763B2 (en) | 2015-01-16 | 2020-01-21 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulation of DUX4 |
US11421229B2 (en) | 2015-02-20 | 2022-08-23 | Baylor College Of Medicine | p63 inactivation for the treatment of heart failure |
US11129844B2 (en) | 2015-03-03 | 2021-09-28 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating MECP2 expression |
WO2016149357A1 (en) | 2015-03-16 | 2016-09-22 | Gen-Probe Incorporated | Methods and compositions for detecting bacterial nucleic acid and diagnosing bacterial vaginosis |
US10407678B2 (en) | 2015-04-16 | 2019-09-10 | Ionis Pharmaceuticals, Inc. | Compositions for modulating expression of C9ORF72 antisense transcript |
US11020417B2 (en) | 2015-06-04 | 2021-06-01 | Sarepta Therapeutics, Inc | Methods and compounds for treatment of lymphocyte-related diseases and conditions |
EP3919619A1 (en) | 2015-07-17 | 2021-12-08 | Alnylam Pharmaceuticals, Inc. | Multi-targeted single entity conjugates |
US10533175B2 (en) | 2015-09-25 | 2020-01-14 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating Ataxin 3 expression |
BR112018007611A2 (pt) | 2015-10-14 | 2018-10-23 | Bio Path Holding Inc | ácidos nucleicos p-etóxi para formulação lipossômica |
MX2018005277A (es) | 2015-11-06 | 2018-08-01 | Ionis Pharmaceuticals Inc | Modular la expresion de apolipoproteina (a). |
EP3389670A4 (en) | 2015-12-04 | 2020-01-08 | Ionis Pharmaceuticals, Inc. | METHODS OF TREATING BREAST CANCER |
WO2017099579A1 (en) | 2015-12-07 | 2017-06-15 | Erasmus University Medical Center Rotterdam | Enzymatic replacement therapy and antisense therapy for pompe disease |
EP4249609A3 (en) | 2016-01-04 | 2023-12-20 | Gen-Probe Incorporated | Methods and compositions for detecting candida species |
EP3400300A4 (en) | 2016-01-05 | 2019-08-07 | Ionis Pharmaceuticals, Inc. | METHODS FOR REDUCING LRRK2 EXPRESSION |
WO2017161168A1 (en) | 2016-03-16 | 2017-09-21 | Ionis Pharmaceuticals, Inc. | Modulation of dyrk1b expression |
AU2017234678A1 (en) | 2016-03-16 | 2018-08-16 | Ionis Pharmaceuticals, Inc. | Methods of modulating KEAP1 |
CA3019635A1 (en) | 2016-03-31 | 2017-10-05 | Baylor Research Institute | Angiopoietin-like protein 8 (angptl8) |
EP3228326A1 (en) | 2016-04-05 | 2017-10-11 | Silence Therapeutics GmbH | Nucleic acid linked to a trivalent glycoconjugate |
EP3443090A4 (en) | 2016-04-14 | 2019-12-11 | University of Florida Research Foundation, Incorporated | USE OF MIR-223-3P AS CANCER THERAPEUTIC AND METHOD FOR THE TREATMENT OF CANCER THEREWITH |
CA3023514A1 (en) | 2016-06-17 | 2017-12-21 | Ionis Pharmaceuticals, Inc. | Modulation of gys1 expression |
NL2017294B1 (en) | 2016-08-05 | 2018-02-14 | Univ Erasmus Med Ct Rotterdam | Natural cryptic exon removal by pairs of antisense oligonucleotides. |
NL2017295B1 (en) | 2016-08-05 | 2018-02-14 | Univ Erasmus Med Ct Rotterdam | Antisense oligomeric compound for Pompe disease |
EP3512525B1 (en) | 2016-09-16 | 2022-07-27 | Bio-Path Holdings, Inc. | Combination therapy with liposomal antisense oligonucleotides |
WO2018067900A1 (en) | 2016-10-06 | 2018-04-12 | Ionis Pharmaceuticals, Inc. | Method of conjugating oligomeric compounds |
JP7167013B2 (ja) | 2016-10-19 | 2022-11-08 | ジェン-プローブ・インコーポレーテッド | C型肝炎ウイルスを検出または定量するための組成物および方法 |
JOP20190104A1 (ar) | 2016-11-10 | 2019-05-07 | Ionis Pharmaceuticals Inc | مركبات وطرق لتقليل التعبير عن atxn3 |
JP7125395B2 (ja) | 2016-11-21 | 2022-08-24 | ジェン-プローブ・インコーポレーテッド | B型肝炎ウイルスを検出または定量化するための組成物および方法 |
EP3548620A4 (en) | 2016-12-02 | 2020-07-22 | Cold Spring Harbor Laboratory | MODULATION OF THE EXPRESSION OF LNC05 |
KR102551664B1 (ko) | 2016-12-22 | 2023-07-05 | 인텔리아 테라퓨틱스, 인크. | 알파-1 항트립신 결핍을 치료하기 위한 조성물 및 방법 |
US11197928B2 (en) | 2017-01-13 | 2021-12-14 | Board Of Regents, The University Of Texas System | Sustained production of high affinity antigen specific antibody by high dose BAFF receptor-targeting mAb-siRNA conjugate |
WO2018165564A1 (en) | 2017-03-09 | 2018-09-13 | Ionis Pharmaceuticals, Inc. | Morpholino modified oligomeric compounds |
EP4056716A1 (en) | 2017-03-24 | 2022-09-14 | Gen-Probe Incorporated | Compositions and methods for detecting or quantifying parainfluenza virus |
CA3225861A1 (en) | 2017-03-25 | 2018-10-04 | Gen-Probe Incorporated | Compositions to detect adenovirus nucleic acids |
WO2018185253A1 (en) | 2017-04-05 | 2018-10-11 | Silence Therapeutics Gmbh | Ligand modified double-stranded nucleic acids |
EP3385272A1 (en) | 2017-04-05 | 2018-10-10 | Silence Therapeutics GmbH | Further novel oligonucleotide-ligand conjugates |
WO2018185252A1 (en) | 2017-04-05 | 2018-10-11 | Silence Therapeutics Gmbh | Nucleic acid conjugates |
AU2018265274B2 (en) | 2017-05-11 | 2021-10-07 | Gen-Probe Incorporated | Compositions and methods for isolating target nucleic acids |
US11667978B2 (en) | 2017-06-07 | 2023-06-06 | Gen-Probe Incorporated | Detecting Babesia species nucleic acid in a sample |
CA3155871A1 (en) | 2017-07-10 | 2019-01-17 | Gen-Probe Incorporated | Analytical systems and methods for nucleic acid amplification using sample assigning parameters |
EP3665309B1 (en) | 2017-08-11 | 2023-02-22 | Gen-Probe Incorporated | Compositions and methods for detecting staphylococcus aureus |
WO2019036613A1 (en) | 2017-08-18 | 2019-02-21 | Ionis Pharmaceuticals, Inc. | MODULATION OF THE NOTCH SIGNALING PATHWAY FOR THE TREATMENT OF RESPIRATORY DISORDERS |
US10517889B2 (en) | 2017-09-08 | 2019-12-31 | Ionis Pharmaceuticals, Inc. | Modulators of SMAD7 expression |
CN111405912A (zh) | 2017-09-29 | 2020-07-10 | 因特利亚治疗公司 | 用于基因组编辑的多核苷酸、组合物及方法 |
BR112020005287A2 (pt) | 2017-09-29 | 2020-09-24 | Intellia Therapeutics, Inc. | composições e métodos para edição de gene ttr e tratar amiloidose attr |
MX2020004600A (es) | 2017-11-02 | 2020-10-05 | Janssen Biopharma Inc | Constructos de oligonucleotidos y usos de estos. |
JP2021501594A (ja) | 2017-11-03 | 2021-01-21 | インテアールエヌエー テクノロジーズ ビー.ヴイ.InteRNA Technologies B.V. | ニューロンの欠損に関連する状態及び/又は疾患を処置及び/又は診断するため、或いはニューロンの再生/発生のための、miRNA分子、等価物、アンタゴミル、又はそれらの供給源 |
TWI809004B (zh) | 2017-11-09 | 2023-07-21 | 美商Ionis製藥公司 | 用於降低snca表現之化合物及方法 |
WO2019099629A1 (en) | 2017-11-17 | 2019-05-23 | Gen-Probe Incorporated | COMPOSITIONS AND METHODS FOR DETECTING C1orf43 NUCLEIC ACID |
US11662281B2 (en) | 2017-12-13 | 2023-05-30 | Gen-Probe Incorporated | Compositions and methods for biological sample processing |
EP3724354A1 (en) | 2017-12-15 | 2020-10-21 | Gen-Probe Incorporated | Compositions and methods for detecting toxigenic clostridium difficile |
WO2019126641A2 (en) | 2017-12-21 | 2019-06-27 | Ionis Pharmaceuticals, Inc. | Modulation of frataxin expression |
JP2021511072A (ja) | 2018-01-15 | 2021-05-06 | アイオニス・ファーマシューティカルズ・インコーポレイテッドIonis Pharmaceuticals,Inc. | Dnm2発現のモジュレーター |
US20190233816A1 (en) | 2018-01-26 | 2019-08-01 | Massachusetts Institute Of Technology | Structure-guided chemical modification of guide rna and its applications |
EP3746225A1 (en) | 2018-01-29 | 2020-12-09 | Gen-Probe Incorporated | Analytical systems and methods |
CN111936150A (zh) | 2018-02-12 | 2020-11-13 | 因特尔纳技术有限公司 | 抗癌微小rna及其脂质制剂 |
US11732260B2 (en) | 2018-03-02 | 2023-08-22 | Ionis Pharmaceuticals, Inc. | Compounds and methods for the modulation of amyloid-β precursor protein |
AU2019228607B2 (en) | 2018-03-02 | 2024-03-07 | Ionis Pharmaceuticals, Inc. | Modulators of IRF4 expression |
WO2019183440A1 (en) | 2018-03-22 | 2019-09-26 | Ionis Pharmaceuticals, Inc. | Methods for modulating fmr1 expression |
EP3549610A1 (en) | 2018-04-05 | 2019-10-09 | Silence Therapeutics GmbH | Nucleic acid conjugates |
JP7275164B2 (ja) | 2018-04-11 | 2023-05-17 | アイオーニス ファーマシューティカルズ, インコーポレーテッド | Ezh2発現の調節因子 |
MX2020011911A (es) | 2018-05-09 | 2021-01-29 | Ionis Pharmaceuticals Inc | Compuestos y metodos para reducir de la expresion de atxn3. |
MX2020011913A (es) | 2018-05-09 | 2021-01-29 | Ionis Pharmaceuticals Inc | Compuestos y metodos para la reduccion de la expresion de fxi. |
WO2019239394A1 (en) | 2018-06-13 | 2019-12-19 | Gen-Probe Incorporated | Compositions and methods for detecting group b streptococcus nucleic acid |
EP3807411A4 (en) | 2018-06-14 | 2022-08-03 | Ionis Pharmaceuticals, Inc. | COMPOUNDS AND METHODS FOR ENHANCING STMN2 EXPRESSION |
TWI833770B (zh) | 2018-06-27 | 2024-03-01 | 美商Ionis製藥公司 | 用於減少 lrrk2 表現之化合物及方法 |
CA3105684A1 (en) | 2018-07-10 | 2020-01-16 | Gen-Probe Incorporated | Methods and systems for detecting and quantifying nucleic acids |
MX2021000922A (es) | 2018-07-25 | 2021-03-31 | Ionis Pharmaceuticals Inc | Compuestos y metodos para reducir la expresion de la atxn2. |
MX2021001070A (es) | 2018-07-31 | 2021-05-27 | Intellia Therapeutics Inc | Composiciones y métodos para editar el gen hidroxiácido oxidasa 1 (hao1) para tratar la hiperoxaluria primaria tipo 1 (ph1). |
WO2020028631A1 (en) | 2018-08-01 | 2020-02-06 | Gen-Probe Incorporated | Compositions and methods for detecting nucleic acids of epstein-barr virus |
JP2021532808A (ja) | 2018-08-08 | 2021-12-02 | ジェン−プローブ・インコーポレーテッド | Mycoplasma genitaliumを検出するための組成物、方法、およびキット |
US20210317461A1 (en) | 2018-08-09 | 2021-10-14 | Verseau Therapeutics, Inc. | Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof |
US20220074002A1 (en) | 2018-08-21 | 2022-03-10 | Gen-Probe Incorporated | Compositions and methods for amplifying, detecting or quantifying human cytomegalovirus |
AU2019324196A1 (en) | 2018-08-24 | 2021-03-18 | Gen-Probe Incorporated | Compositions and methods for detecting bacterial nucleic acid and diagnosing bacterial vaginosis |
EP3856934A2 (en) | 2018-09-27 | 2021-08-04 | Gen-Probe Incorporated | COMPOSITIONS AND METHODS FOR DETECTING BORDETELLA PERTUSSIS AND BORDETELLA
PARAPERTUSSIS NUCLEIC ACID |
JP2022502055A (ja) | 2018-09-28 | 2022-01-11 | インテリア セラピューティクス,インコーポレイテッド | 乳酸デヒドロゲナーゼ(ldha)遺伝子編集のための組成物及び方法 |
MX2021004214A (es) | 2018-10-16 | 2021-07-15 | Intellia Therapeutics Inc | Composiciones y metodos de inmunoterapia. |
KR20210102881A (ko) | 2018-10-18 | 2021-08-20 | 인텔리아 테라퓨틱스, 인크. | 인자 ix의 발현을 위한 조성물 및 방법 |
MX2021004276A (es) | 2018-10-18 | 2021-09-08 | Intellia Therapeutics Inc | Composiciones y metodos para tratar deficiencia de alfa-1 antitripsina. |
JP2022512726A (ja) | 2018-10-18 | 2022-02-07 | インテリア セラピューティクス,インコーポレーテッド | 核酸構築物及び使用方法 |
JP7472121B2 (ja) | 2018-10-18 | 2024-04-22 | インテリア セラピューティクス,インコーポレーテッド | アルブミン遺伝子座からの導入遺伝子発現のための組成物及び方法 |
WO2020086546A1 (en) | 2018-10-22 | 2020-04-30 | Gen-Probe Incorporated | Compositions and methods for amplifying, detecting or quantifying human polyomavirus bk virus |
TW202028222A (zh) | 2018-11-14 | 2020-08-01 | 美商Ionis製藥公司 | Foxp3表現之調節劑 |
PE20211869A1 (es) | 2018-11-15 | 2021-09-21 | Ionis Pharmaceuticals Inc | Moduladores de la expresion de irf5 |
TW202030333A (zh) | 2018-12-20 | 2020-08-16 | 美商簡 探針公司 | 用於檢測瘧原蟲物種核酸之組成物及方法 |
SG11202107399WA (en) | 2019-01-31 | 2021-08-30 | Ionis Pharmaceuticals Inc | Modulators of yap1 expression |
US11279932B2 (en) | 2019-02-27 | 2022-03-22 | Ionis Pharmaceuticals, Inc. | Modulators of MALAT1 expression |
EP4389916A2 (en) | 2019-03-22 | 2024-06-26 | Gen-Probe Incorporated | Compositions and methods for detecting group a streptococcus |
WO2020198706A1 (en) | 2019-03-28 | 2020-10-01 | Intellia Therapeutics, Inc. | Compositions and methods for ttr gene editing and treating attr amyloidosis comprising a corticosteroid or use thereof |
TW202102529A (zh) | 2019-03-28 | 2021-01-16 | 美商英特利亞醫療公司 | 用於多肽表現之多核苷酸、組合物及方法 |
AU2020244887A1 (en) | 2019-03-28 | 2021-11-11 | Intellia Therapeutics, Inc. | Compositions and methods comprising a TTR guide RNA and a polynucleotide encoding an RNA-guided DNA binding agent |
KR20210144822A (ko) | 2019-03-29 | 2021-11-30 | 아이오니스 파마수티컬즈, 인코포레이티드 | Ube3a-ats를 조절하기 위한 화합물 및 방법 |
EP4371667A2 (en) | 2019-05-03 | 2024-05-22 | Gen-Probe Incorporated | Receptacle transport system for an analytical system |
WO2021003331A1 (en) | 2019-07-03 | 2021-01-07 | Gen-Probe Incorporated | Oligonucleotides for use in determining the presence of trichomonas vaginalis in a sample |
EP3956450A4 (en) | 2019-07-26 | 2022-11-16 | Ionis Pharmaceuticals, Inc. | COMPOUNDS AND METHODS FOR MODULATION OF GFAP |
JP2022544587A (ja) | 2019-08-15 | 2022-10-19 | アイオーニス ファーマシューティカルズ, インコーポレーテッド | 結合修飾オリゴマー化合物及びその使用 |
AU2020335996A1 (en) | 2019-08-23 | 2022-03-31 | Gen-Probe Incorporated | Compositions, methods and kits for detecting Treponema pallidum |
EP4022057A1 (en) | 2019-08-27 | 2022-07-06 | Vertex Pharmaceuticals Incorporated | Compositions and methods for treatment of disorders associated with repetitive dna |
AU2020343334A1 (en) | 2019-09-05 | 2022-04-07 | Gen-Probe Incorporated | Detection of Chlamydia trachomatis nucleic acid variants |
WO2021097358A1 (en) | 2019-11-14 | 2021-05-20 | Gen-Probe Incorporated | Compositions and methods for capturing target nucleic acids |
SG10201914033YA (en) | 2019-12-31 | 2021-07-29 | Wilmar International Ltd | Polypeptides with Lipase Activity and Uses Thereof |
WO2021144587A1 (en) | 2020-01-16 | 2021-07-22 | Dnae Diagnostics Limited | Compositions, kits and methods for isolating target polynucleotides |
US20210239663A1 (en) | 2020-01-31 | 2021-08-05 | Regeneron Pharmaceuticals, Inc. | Use of liquid chromatography and mass spectrometry to characterize oligonucleotides |
CR20220485A (es) | 2020-02-28 | 2022-11-10 | Ionis Pharmaceuticals Inc | Compuestos y métodos para modular smn2 |
AU2021263745A1 (en) | 2020-04-28 | 2022-12-08 | Intellia Therapeutics, Inc. | Methods of in vitro cell delivery |
MX2022013707A (es) | 2020-05-01 | 2022-12-07 | Ionis Pharmaceuticals Inc | Compuestos y metodos para modular atxn1. |
US20230220499A1 (en) | 2020-05-07 | 2023-07-13 | Grifols Diagnostic Solutions Inc. | Methods and compositions for detecting sars-cov-2 nucleic acid |
EP3922720A1 (en) | 2020-06-09 | 2021-12-15 | Universidad de Murcia | Therapy to prevent adverse cardiac remodeling following an acute myocardial infarction |
CN116096899A (zh) | 2020-06-29 | 2023-05-09 | Ionis制药公司 | 调节plp1的化合物和方法 |
CA3188657A1 (en) | 2020-07-17 | 2022-01-20 | Gen-Probe Incorporated | Detection of macrolide-resistant mycoplasma genitalium |
WO2022034555A1 (en) | 2020-08-13 | 2022-02-17 | Janssen Biopharma, Inc. | Polynucleotide constructs and uses thereof |
WO2022056000A1 (en) | 2020-09-09 | 2022-03-17 | Vertex Pharmaceuticals Incorporated | Compositions and methods for treatment of duchenne muscular dystrophy |
CA3177256A1 (en) | 2020-10-21 | 2022-04-28 | Gen-Probe Incorporated | Fluid container management system |
EP4240854A1 (en) | 2020-11-06 | 2023-09-13 | Vertex Pharmaceuticals Incorporated | Compositions and methods for treatment of dm1 with slucas9 and sacas9 |
KR20230108728A (ko) | 2020-11-18 | 2023-07-18 | 아이오니스 파마수티컬즈, 인코포레이티드 | 앤지오텐시노겐 발현을 조절하기 위한 화합물 및 방법 |
EP4259792A1 (en) | 2020-12-11 | 2023-10-18 | Intellia Therapeutics, Inc. | Polynucleotides, compositions, and methods for genome editing involving deamination |
KR20230130635A (ko) | 2020-12-11 | 2023-09-12 | 인텔리아 테라퓨틱스, 인크. | 세포에서 mhc 클래스 ii를 감소시키기 위한 조성물및 방법 |
CA3205042A1 (en) | 2020-12-23 | 2022-06-30 | Intellia Therapeutics, Inc. | Compositions and methods for genetically modifying ciita in a cell |
CA3206284A1 (en) | 2020-12-23 | 2022-06-30 | Intellia Therapeutics, Inc. | Compositions and methods for reducing hla-a in a cell |
WO2022147133A1 (en) | 2020-12-30 | 2022-07-07 | Intellia Therapeutics, Inc. | Engineered t cells |
EP4277658A1 (en) | 2021-01-15 | 2023-11-22 | Board of Regents, The University of Texas System | A trans-complementation system for sars-cov-2 |
WO2022170172A1 (en) | 2021-02-08 | 2022-08-11 | Intellia Therapeutics, Inc. | Natural killer cell receptor 2b4 compositions and methods for immunotherapy |
EP4288089A2 (en) | 2021-02-08 | 2023-12-13 | Intellia Therapeutics, Inc. | T-cell immunoglobulin and mucin domain 3 (tim3) compositions and methods for immunotherapy |
WO2022170194A2 (en) | 2021-02-08 | 2022-08-11 | Intellia Therapeutics, Inc. | Lymphocyte activation gene 3 (lag3) compositions and methods for immunotherapy |
WO2022182957A1 (en) | 2021-02-26 | 2022-09-01 | Vertex Pharmaceuticals Incorporated | Compositions and methods for treatment of myotonic dystrophy type 1 with crispr/sacas9 |
WO2022182959A1 (en) | 2021-02-26 | 2022-09-01 | Vertex Pharmaceuticals Incorporated | Compositions and methods for treatment of myotonic dystrophy type 1 with crispr/slucas9 |
EP4307916A1 (en) | 2021-03-15 | 2024-01-24 | Gen-Probe Incorporated | Compositions and methods for biological sample processing |
EP4314295A1 (en) | 2021-03-26 | 2024-02-07 | The Board Of Regents Of The University Of Texas System | Nucleotide editing to reframe dmd transcripts by base editing and prime editing |
WO2022229851A1 (en) | 2021-04-26 | 2022-11-03 | Crispr Therapeutics Ag | Compositions and methods for using slucas9 scaffold sequences |
WO2022234519A1 (en) | 2021-05-05 | 2022-11-10 | Crispr Therapeutics Ag | Compositions and methods for using sacas9 scaffold sequences |
BR112023026050A2 (pt) | 2021-06-18 | 2024-03-05 | Ionis Pharmaceuticals Inc | Compostos e métodos para reduzir expressão de ifnar1 |
CA3224995A1 (en) | 2021-06-22 | 2022-12-29 | Intellia Therapeutics, Inc. | Methods for in vivo editing of a liver gene |
GB202110479D0 (en) | 2021-07-21 | 2021-09-01 | Dnae Diagnostics Ltd | Compositions, kits and methods for sequencing target polynucleotides |
GB202110485D0 (en) | 2021-07-21 | 2021-09-01 | Dnae Diagnostics Ltd | Compositions, kits and methods for sequencing target polynucleotides |
CA3226451A1 (en) | 2021-07-21 | 2023-01-26 | Sam Reed | Method and system comprising a cartridge for sequencing target polynucleotides |
EP4382624A2 (en) | 2021-07-27 | 2024-06-12 | Gen-Probe Incorporated | Compositions and methods for detecting salmonella and at least one of c. jejuni, c. coli, shigella, and stec |
WO2023018637A1 (en) | 2021-08-09 | 2023-02-16 | Vertex Pharmaceuticals Incorporated | Gene editing of regulatory elements |
CN117940153A (zh) | 2021-08-24 | 2024-04-26 | 因特利亚治疗公司 | 用于基于细胞的疗法的程序性细胞死亡蛋白1(pd1)组合物和方法 |
WO2023039444A2 (en) | 2021-09-08 | 2023-03-16 | Vertex Pharmaceuticals Incorporated | Precise excisions of portions of exon 51 for treatment of duchenne muscular dystrophy |
WO2023049708A1 (en) | 2021-09-22 | 2023-03-30 | Herbalife International Of America, Inc. | Methods and compositions for identifying botanical material using arms-pcr |
AU2022382975A1 (en) | 2021-11-03 | 2024-05-02 | Intellia Therapeutics, Inc. | Polynucleotides, compositions, and methods for genome editing |
WO2023081200A2 (en) | 2021-11-03 | 2023-05-11 | Intellia Therapeutics, Inc. | Cd38 compositions and methods for immunotherapy |
TW202345911A (zh) | 2022-03-08 | 2023-12-01 | 美商維泰克斯製藥公司 | 用於治療杜興氏肌肉失養症(duchenne muscular dystrophy)之部分外顯子44、50及53之精確切除 |
WO2023172926A1 (en) | 2022-03-08 | 2023-09-14 | Vertex Pharmaceuticals Incorporated | Precise excisions of portions of exons for treatment of duchenne muscular dystrophy |
WO2023185697A2 (en) | 2022-03-29 | 2023-10-05 | Accuredit Therapeutics (Suzhou) Co., Ltd. | Compositions and methods for treatment of transthyretin amyloidosis |
TW202405173A (zh) | 2022-04-18 | 2024-02-01 | 美商維泰克斯製藥公司 | 用於增強aav療法及降低aav向肝臟之趨性的組合物及方法 |
WO2023205148A1 (en) | 2022-04-19 | 2023-10-26 | Intellia Therapeutics, Inc. | Chimeric antigen receptor compositions and uses |
TW202408595A (zh) | 2022-06-16 | 2024-03-01 | 美商英特利亞醫療公司 | 用於對細胞進行遺傳修飾之方法及組合物 |
WO2023245109A2 (en) | 2022-06-16 | 2023-12-21 | Intellia Therapeutics, Inc. | Compositions and methods for genomic editing |
WO2023245108A2 (en) | 2022-06-16 | 2023-12-21 | Intellia Therapeutics, Inc. | Compositions and methods for reducing mhc class i in a cell |
WO2024006955A1 (en) | 2022-06-29 | 2024-01-04 | Intellia Therapeutics, Inc. | Engineered t cells |
WO2024020352A1 (en) | 2022-07-18 | 2024-01-25 | Vertex Pharmaceuticals Incorporated | Tandem guide rnas (tg-rnas) and their use in genome editing |
EP4311579A1 (en) | 2022-07-29 | 2024-01-31 | Association Française contre les Myopathies | B cell-specific mab-sirna conjugates improve myasthenia |
WO2024026474A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle |
WO2024035952A1 (en) | 2022-08-12 | 2024-02-15 | Remix Therapeutics Inc. | Methods and compositions for modulating splicing at alternative splice sites |
WO2024054924A1 (en) | 2022-09-08 | 2024-03-14 | Gen-Probe Incorporated | Method of detecting nucleic acid analytes using dual-specificity primers |
WO2024061296A2 (en) | 2022-09-22 | 2024-03-28 | Accuredit Therapeutics (Suzhou) Co., Ltd. | Compositions and methods for treatment of hypercholesterolemia and/or cardiovascular disease |
WO2024098002A1 (en) | 2022-11-04 | 2024-05-10 | Regeneron Pharmaceuticals, Inc. | Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle |
WO2024102677A1 (en) | 2022-11-08 | 2024-05-16 | Orna Therapeutics, Inc. | Circular rna compositions |
WO2024107765A2 (en) | 2022-11-14 | 2024-05-23 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1340645C (en) * | 1987-04-17 | 1999-07-13 | Victor E. Marquez | Acid stable dideoxynucleosides active against the cytopathic effects of human immunodeficiency virus |
IL90359A0 (en) * | 1988-05-26 | 1989-12-15 | University Patents Inc | Nucleoside and polynucleotide thiophosphoramidite and phosphorodithioate compounds and their production |
US5216141A (en) * | 1988-06-06 | 1993-06-01 | Benner Steven A | Oligonucleotide analogs containing sulfur linkages |
JPH0231686A (ja) * | 1988-07-22 | 1990-02-01 | Yuki Gosei Kogyo Co Ltd | トリフルオロチミジンの製造方法 |
JPH0725785B2 (ja) * | 1989-01-11 | 1995-03-22 | 日本臓器製薬株式会社 | アデノシン誘導体及び該化合物を有効成分として含有する医薬組成物 |
FR2642074B1 (fr) * | 1989-01-20 | 1994-04-29 | Oris Ind | Derives de molecules polyhydroxylees permettant l'introduction d'au moins une ramification dans un oligonucleotide |
GB8920534D0 (en) * | 1989-09-11 | 1989-10-25 | Wellcome Found | Antiviral compounds |
US5378825A (en) * | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
HU217036B (hu) * | 1990-08-03 | 1999-11-29 | Sanofi | Eljárás génexpresszió gátlására alkalmas vegyületek előállítására |
US5596086A (en) * | 1990-09-20 | 1997-01-21 | Gilead Sciences, Inc. | Modified internucleoside linkages having one nitrogen and two carbon atoms |
AU3250093A (en) * | 1991-12-12 | 1993-07-19 | Gilead Sciences, Inc. | Nuclease stable and binding competent oligomers and methods for their use |
NZ245720A (en) * | 1992-01-22 | 1995-12-21 | Hoechst Ag | Oligonucleotide analogues; use as gene expression inhibitor or dna probe |
AU678968B2 (en) * | 1992-05-29 | 1997-06-19 | Howard Florey Institute Of Experimental Physiology And Medicine | Oligonucleotide-polyamide conjugates |
-
1991
- 1991-05-21 US US07/703,619 patent/US5378825A/en not_active Expired - Lifetime
-
1992
- 1992-05-21 BR BR9206027A patent/BR9206027A/pt not_active Application Discontinuation
- 1992-05-21 EP EP92913119A patent/EP0586570B1/en not_active Expired - Lifetime
- 1992-05-21 IE IE185092A patent/IE921850A1/en not_active IP Right Cessation
- 1992-05-21 HU HU9303289A patent/HU221806B1/hu active IP Right Grant
- 1992-05-21 AU AU19986/92A patent/AU662538B2/en not_active Ceased
- 1992-05-21 IE IE184992A patent/IE921849A1/en not_active Application Discontinuation
- 1992-05-21 BR BR9206026A patent/BR9206026A/pt not_active Application Discontinuation
- 1992-05-21 AT AT92912190T patent/ATE191933T1/de not_active IP Right Cessation
- 1992-05-21 EP EP99203016A patent/EP1004593A3/en not_active Withdrawn
- 1992-05-21 CA CA002103464A patent/CA2103464A1/en not_active Abandoned
- 1992-05-21 WO PCT/US1992/004294 patent/WO1992020822A1/en active IP Right Grant
- 1992-05-21 EP EP92912190A patent/EP0586520B1/en not_active Expired - Lifetime
- 1992-05-21 AT AT92913119T patent/ATE196321T1/de not_active IP Right Cessation
- 1992-05-21 JP JP5500301A patent/JP2711180B2/ja not_active Expired - Fee Related
- 1992-05-21 AU AU21502/92A patent/AU666121B2/en not_active Expired
- 1992-05-21 CA CA002103378A patent/CA2103378A1/en not_active Abandoned
- 1992-05-21 DE DE69231441T patent/DE69231441T2/de not_active Expired - Lifetime
- 1992-05-21 HU HU9303290A patent/HUT65941A/hu unknown
- 1992-05-21 DE DE69230935T patent/DE69230935T2/de not_active Expired - Lifetime
- 1992-05-21 KR KR1019930703559A patent/KR0156945B1/ko not_active IP Right Cessation
- 1992-05-21 KR KR1019930703560A patent/KR0155574B1/ko not_active IP Right Cessation
- 1992-05-21 WO PCT/US1992/004305 patent/WO1992020823A1/en active IP Right Grant
- 1992-05-21 JP JP5500305A patent/JP2625257B2/ja not_active Expired - Lifetime
-
1993
- 1993-11-18 NO NO934179A patent/NO308703B1/no not_active Application Discontinuation
- 1993-11-18 FI FI935114A patent/FI935114A/fi unknown
- 1993-11-18 NO NO934180A patent/NO934180L/no unknown
- 1993-11-18 FI FI935113A patent/FI113870B/fi not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH06504067A (ja) | 主鎖修飾されたオリゴヌクレオチド類似体 | |
US5965721A (en) | Backbone modified oligonucleotide analogues | |
JP3535519B2 (ja) | N−2置換プリン類 | |
US5618704A (en) | Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling | |
US6369209B1 (en) | Oligonucleotides having A-DNA form and B-DNA form conformational geometry | |
US5777092A (en) | Heteroatomic oligonucleoside linkages | |
US5602240A (en) | Backbone modified oligonucleotide analogs | |
US6087482A (en) | Heteroatomic oligonucleoside linkages | |
IE83315B1 (en) | Backbone modified oligonucleotide analogs | |
US7119184B2 (en) | Oligonucleotides having A-DNA form and B-DNA form conformational geometry | |
JP2879973B2 (ja) | ヘテロ原子によるオリゴヌクレオシド連結 | |
WO1994022886A9 (en) | Heteroatomic oligonucleoside linkages | |
WO1994022894A1 (en) | Backbone modified oligonucleotide analogs and preparation thereof through radical coupling |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071024 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081024 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081024 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091024 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091024 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101024 Year of fee payment: 13 |
|
LAPS | Cancellation because of no payment of annual fees | ||
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R370 | Written measure of declining of transfer procedure |
Free format text: JAPANESE INTERMEDIATE CODE: R370 |